小野澤 真弘 (オノザワ マサヒロ)

北海道大学病院 臨床研修センター講師

研究者基本情報

■ 学位
  • 博士(医学), 北海道大学
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード
  • 白血病遺伝学
  • 造血細胞移植
  • Hematological cell transplantation
研究分野
  • ライフサイエンス, 遺伝学
  • ライフサイエンス, 血液、腫瘍内科学
  • ライフサイエンス, 分子生物学
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2019年04月 - 現在
    北海道大学病院, 臨床研修センター, 講師
  • 2018年10月 - 2019年03月
    北海道大学病院, 血液内科, 助教
  • 2014年04月 - 2018年09月
    北海道大学大学院医学研究科, 医学教育推進センター, 助教
  • 2010年04月 - 2014年03月
    米国国立衛生研究所/国立がん研究所, 遺伝学部門, ポストドクトラルフェロー
  • 2007年04月 - 2010年03月
    北海道大学病院, 第三内科, 助教
  • 2001年04月 - 2003年03月
    市立旭川病院, 血液内科
  • 2000年04月 - 2001年03月
    市立札幌病院, 研修医
  • 1999年05月 - 2000年03月
    北海道大学病院, 内科研修医
学歴
  • 2003年04月 - 2007年03月, 北海道大学, 大学院医学研究科
  • 1993年04月 - 1999年03月, 北海道大学, 医学部

研究活動情報

■ 受賞
  • 2016年04月, 日本学術振興会, 基盤研究(C)
    次世代シークエンスによる再発難治性急性白血病のゲノム構造の解析
    小野澤 真弘
  • 2014年10月, かなえ医薬振興財団, 研究助成金
    次世代シークエンス技術を用いたゲノム損傷部位定量化による二次性 白血病の診断指標の確立
    小野澤 真弘
  • 2014年09月, 日本学術振興会, 研究活動スタート支援
    テロメラーゼによるDNA二重鎖切断修復機構の解明
    小野澤 真弘
  • 2013年12月, 米国血液学会, 優秀抄録賞
    小野澤 真弘
  • 2010年04月, 日本学術振興会, 海外特別研究員
    小野澤 真弘
  • 2008年, 北海道医学会賞
    日本国
  • 2004年, 第27回造血細胞移植学会学会奨励賞
    日本国
■ 論文
  • Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.
    Toshihiro Matsukawa; Shota Yoshida; Masahiro Onozawa; Fumiaki Fujii; Jun Nagai; Tomoki Takahashi; Shuichi Ota; Junichi Hashiguchi; Akio Mori; Takuto Miyagishima; Makoto Ibata; Yasutaka Kakinoki; Tatsuo Oyake; Satoshi Yamamoto; Toshiaki Hayashi; Kentaro Wakasa; Tomoyuki Saga; Tetsuya Igarashi; Satoshi Iyama; Yutaka Tsutsumi; Katsuya Fujimoto; Masaaki Adachi; Masahiro Yoshida; Daigo Hashimoto; Takanori Teshima
    Hematology (Amsterdam, Netherlands), 31, 1, 2628479, 2628479, 2026年12月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) are associated with poor prognosis, but the impact relative to de novo AML remains controversial. We investigated clinical and genetic features in a multicenter Japanese cohort before CPX-351 approval. METHODS: We retrospectively analyzed 294 patients with newly diagnosed AML registered in the Hokkaido Leukemia Net between 2022 and 2023. Propensity score matching was used to adjust baseline variables. Genetic profiles were assessed in 160 matched patients. RESULTS: In the matched cohort, sAML/AML-MRC did not show inferior overall survival compared with non-sAML/non-AML-MRC (P = 0.90). Adverse karyotypes were the predominant determinant among sAML/AML-MRC. Among sAML/AML-MRC patients, adverse karyotypes were associated with poorer survival than those without adverse karyotypes (P = 0.0075). In contrast, non-sAML/non-AML-MRC groups did not affect survival regardless of adverse karyotypes (P = 0.51). Among 65 patients with ELN 2017 adverse-risk, those with TP53 mutations had markedly shorter survival than those with TP53 wild-type (P = 0.018). CONCLUSIONS: sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
  • Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.
    Masahiro Onozawa; Shigeru Kusumoto; Yachiyo Kuwatsuka; Takayoshi Miyazono; Masatsugu Tanaka; Yuho Najima; Kohei Okada; Souichi Shiratori; Takayuki Sato; Junya Kanda; Yuichiro Inagaki; Tohru Murayama; Kaoru Hatano; Koichi Onodera; Masatoshi Sakurai; Shinya Endo; Takahiro Kumode; Hidehiro Itonaga; Yukiyoshi Moriuchi; Nobuhiro Kanemura; Tatsuya Imi; Taro Edahiro; Nobuaki Fukushima; Masahiro Oura; Shunsuke Yui; Mitsumasa Watanabe; Tomomi Toubai; Toshihiko Ando; Daisuke Nakamura; Masaharu Tamaki; Yasutaka Kakinoki; Takahiro Okada; Nobuaki Nakano; Takayoshi Tachibana; Hiroaki Shimizu; Shuichi Ota; Shinsuke Iida; Masaya Sugiyama; Yoshiko Atsuta; Takanori Teshima; Tomoharu Yoshizumi; Masashi Mizokami
    Transplantation and cellular therapy, 2026年05月17日, [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with resolved HBV infection undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Although HBV DNA-guided preemptive nucleos(t)ide analog therapy prevents HBV-related hepatitis, strategies to prevent HBV reactivation itself remain limited. Hepatitis B vaccination after allo-HCT has been suggested as a potential preventive strategy, but prospective randomized evidence is lacking. To evaluate whether hepatitis B (HepB) vaccination reduces HBV reactivation after allo-HCT and to examine the association between vaccination-induced anti-hepatitis B surface antibody (anti-HBs) response and protection against HBV reactivation. In this multicenter randomized controlled trial (UMIN000034113), adults who were hepatitis B surface antigen-negative and anti-hepatitis B core antigen-positive and underwent first allo-HCT were prospectively enrolled. At 140 days post-HCT, patients without HBV reactivation were randomized to receive HepB vaccination or no vaccination. HBV DNA levels and anti-HBs titers were centrally monitored for 2 years after transplantation. The primary endpoint was HBV reactivation, defined as HBV DNA ≥ 1.3 log IU/mL. Vaccine response was defined as anti-HBs response, requiring both an increase in anti-HBs from baseline and a post-vaccination anti-HBs ≥ 10 mIU/mL. Among 109 enrolled patients, 64 were randomized. With a median HBV DNA follow-up of 19.4 months, HBV reactivation occurred in 6 of 33 patients in the vaccination group, including 2 who experienced reactivation before receiving the first vaccine dose, and 9 of 31 patients in the control group. Probabilities of HBV reactivation were 19.8% and 37.9% in the HepB vaccination and control groups, respectively, at 18 months after randomization (P = .205). Baseline anti-HBs <10 mIU/mL was a significant risk factor for HBV reactivation. No HBV-related hepatitis was observed. Vaccine responses were achieved in 9 of 29 patients after the initial series and in 5 of 10 after the additional series. Importantly, HBV reactivation did not occur after patients achieved anti-HBs response, although several reactivation events occurred before vaccination or before anti-HBs response was achieved. No severe vaccine-related adverse events were observed. Although HepB vaccination did not significantly reduce HBV reactivation, it was feasible and induced anti-HBs response in a subset of patients. Achieving vaccine-induced anti-HBs response may provide protective immunity against HBV reactivation after allo-HCT.
  • Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.
    Shota Yokoyama; Masahiro Onozawa; Hiroyuki Kimura; Takahide Ara; Jun Nagai; Shota Yoshida; Naoki Miyashita; Toshihiro Matsukawa; Hideki Goto; Shinsuke Hirabayashi; Minoru Kanaya; Akio Mori; Daisuke Hidaka; Junichi Hashiguchi; Kentaro Wakasa; Makoto Ibata; Yukari Takeda; Takuto Miyagishima; Satoshi Yamamoto; Katsuya Fujimoto; Toma Suzuki; Tomoyuki Saga; Hajime Sakai; Yasutaka Kakinoki; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
    International journal of hematology, 2026年04月22日, [国内誌]
    英語, 研究論文(学術雑誌), Chronic myelogenous leukemia that carries the BCR::ABL1 fusion gene without cytogenetically detectable Philadelphia (Ph) chromosomes is termed masked Ph. However, the prevalence and clinical relevance of masked Ph in acute lymphoblastic leukemia (ALL) remain unclear. Using the Hokkaido Leukemia Net real-world multicenter cohort, we analyzed 160 B-cell ALL patients diagnosed between 2017 and 2024 with available cytogenetic and molecular data. Among 92 BCR::ABL1-positive cases, 19 (20.7%) lacked a cytogenetically visible Ph chromosome and were classified as masked-Ph ALL. Compared with Ph + ALL, masked-Ph patients were older and had lower white blood cell counts and bone marrow blast percentages at diagnosis. Most BCR::ABL1-positive patients received tyrosine kinase inhibitors (TKIs) during induction, resulting in comparable complete remission rates and similar overall survival between masked-Ph and Ph + ALL; both groups showed superior outcomes compared with BCR::ABL1-negative ALL. The number of metaphases analyzed by G-banding was significantly lower in masked-Ph ALL, suggesting underdetection by conventional cytogenetics. One case exhibited an atypical FISH pattern consistent with a cryptic microinsertion. These findings indicate that masked-Ph ALL is relatively common and may be overlooked without molecular testing, underscoring the importance of incorporating RT-PCR and FISH at diagnosis.
  • A Case of Acute Myeloid Leukemia with MOZ::TIF2 Fusion Gene Resulting from a Novel Breakpoint.
    Toma Suzuki; Masahiro Onozawa; Minoru Kanaya; Takeshi Kondo; Shunsuke Sugimura; Jun Nagai; Keito Yokoyama; Yumika Saito; Shota Yoshida; Shinpei Harada; Keito Suto; Yuta Hasegawa; Takahide Ara; Hideki Goto; Daigo Hashimoto; Takanori Teshima
    Internal medicine (Tokyo, Japan), 2026年04月21日, [国内誌]
    英語, 研究論文(学術雑誌), We report a rare case of acute myeloid leukemia (AML) harboring an MOZ::TIF2 fusion gene with a previously unreported breakpoint. A 36-year-old man was diagnosed with AML involving inv(8)(p11.2q13). Reverse transcriptase-polymerase chain reaction (RT-PCR) initially failed to detect the conventional MOZ exon16::TIF2 exon14 fusion associated with inv(8)(p11.2q13); however, further sequencing identified a novel breakpoint of MOZ exon14::TIF2 exon12, with an additional shorter transcript lacking TIF2 exon13. MOZ::TIF2-positive AML is extremely rare, with only eight cases previously reported, and adult cases appear to have particularly poor outcomes. Our case highlights the diagnostic challenges and aggressive clinical behavior associated with MOZ::TIF2-rearranged AML.
  • Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.
    Shingo Nojima; Toru Miyajima; Reiki Ogasawara; Shota Yoshida; Hiroyuki Kimura; Rintaro Nozu; Fuka Horikita; Takahide Ara; Toshihiro Matsukawa; Souichi Shiratori; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
    Leukemia & lymphoma, 1, 4, 2026年04月08日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.
    Fumiaki Fujii; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Daisuke Hidaka; Reiki Ogasawara; Mutsumi Takahata; Junichi Hashiguchi; Shota Yokoyama; Masahiro Chiba; Tomoyuki Saga; Taku Shimizu; Ikumi Kasahara; Akio Shigematsu; Katsuya Fujimoto; Satoshi Iyama; Tetsuyuki Igarashi; Shinichi Ito; Yoshihito Haseyama; Mizuha Kosugi-Kanaya; Takeshi Kondo; Takanori Teshima
    International journal of hematology, 2026年03月19日, [国内誌]
    英語, 研究論文(学術雑誌), Venetoclax (VEN), a BCL-2 inhibitor, was approved in Japan in March 2021, for acute myeloid leukemia (AML). We retrospectively analyzed the impact of VEN approval on treatment patterns and outcomes in older AML patients aged 65-74 years unfit for intensive chemotherapy in Japan. Using the Hokkaido Leukemia Net database, we categorized 101 patients into pre-VEN (n = 46) and post-VEN (n = 55) cohorts, excluding those who had acute promyelocytic leukemia or received intensive chemotherapy. Following VEN approval, VEN + azacitidine (AZA) became the most frequently used initial regimen (56%). Despite higher rates of TP53 mutations and complex karyotypes (35.5%), VEN + AZA achieved comparable response rates (CR + CRi: 64.5%) and overall survival (OS, median 11.7 months) to r7 + 3 (CR + CRi: 64.5%, median OS: 13.1 months), and superior outcomes to cytarabine + aclarubicin + G-CSF (CAG, CR + CRi 37.5%, median OS 6.8 months) or AZA monotherapy (CR + CRi 12.5%, median OS 4.5 months). Early mortality at 60 days from diagnosis was lower with VEN + AZA (3.2%) than with reduced-dose cytarabine plus anthracycline (r7 + 3) (12.9%), CAG (26.7%), or AZA monotherapy (18.8%). Our findings demonstrate a substantial shift in real-world treatment practices following VEN approval and suggest that VEN + AZA is an effective option for older AML patients with adverse genetic features.
  • Clustering of students in pre-clinical medical education and identification of academic performance profiles: does online education work for all medical students?
    Houman Goudarzi; Masahiro Onozawa; Yoichi M. Ito; Makoto Takahashi
    BMC Medical Education, 2026年02月06日
    研究論文(学術雑誌)
  • Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.
    Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
    Transplantation and cellular therapy, 2025年11月06日, [国際誌]
    英語, 研究論文(学術雑誌), Tacrolimus (Tac) and methotrexate (MTX) are standard graft-versus-host disease (GVHD) prophylaxis for umbilical cord blood transplantation (CBT); however, the optimal dose of MTX for CBT remains to be determined. We previously showed the safety and efficacy of reduced-dose MTX (mini-MTX; 5 mg/m2 on days 1, 3, and 6) combined with Tac as GVHD prophylaxis for CBT in a single-center retrospective study. Here we report a multicenter observational study in the North Japan Hematology Study Group (NJHSG; NJHSG-CBT18) conducted to evaluate transplantation outcomes according to GVHD prophylaxis in single-unit CBT, in which patients with hematologic malignancies scheduled for CBT were prospectively registered and followed for 2 years after CBT. A total of 112 patients were registered in NJHSG-CBT18, with a median age of 51 years. Eighty-nine patients received Tac + mini-MTX, 19 patients received Tac + mycophenolate mofetil (MMF), and 4 patients received Tac only as GVHD prophylaxis. Multivariate analysis identified GVHD prophylaxis other than Tac + mini-MTX as a significant risk factor for nonrelapse mortality (NRM) (hazard ratio [HR], 0.160; 95% confidence interval [CI], 0.065 to 0.391; P < .001), overall survival (OS) (HR, 2.971; 95% CI, 1.558 to 5.663; P < .001), progression-free survival (PFS) (HR, 2.383; 95% CI, 1.345 to 4.222; P = .003), and GVHD-free, relapse-free survival (GRFS) (HR, 3.075; 95% CI, 1.799 to 5.256; P < .001). In a comparison of clinical outcomes between the mini-MTX and MMF groups, the cumulative incidences of pre-engraftment immune reaction (5.7% versus 42.1%; P < .001), human herpesvirus 6 encephalitis (2.3% versus 15.8%, P = .011), grade II-IV acute GVHD (14.6% versus 47.4%, P < .001), and NRM (1.1% versus 52.6%, P < .001) were significantly lower and the cumulative incidence of immunosuppressant discontinuation was significantly higher (66.3% versus 18.4%, P = .004) in the mini-MTX group compared to the MMF group, while rates of chronic GVHD and relapse were comparable between the groups. The probabilities of OS (70.6% versus 31.6%, P < .001), PFS (58.1 versus 14.0%, P < .001), and GRFS (44.9% versus 5.1%, P < .001) were significantly higher in the mini-MTX group. Multivariate analysis of risk factors for OS in the mini-MTX group identified high-risk or very high-risk refined Disease Risk Index (rDRI) (HR, 3.896; 95% CI, 1.575 to 9.637; P = .003) and high HCT-CI (HR, 3.338; 95% CI, 1.301 to 8.569; P = .012) as significant risk factors for OS. Our data indicate that a combination of Tac + mini-MTX is safe and effective GVHD prophylaxis in CBT.
  • Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
    Mark J Levis; Mehdi Hamadani; Brent R Logan; Richard J Jones; Anurag K Singh; Mark R Litzow; John R Wingard; Esperanza B Papadopoulos; Alexander E Perl; Robert J Soiffer; Celalettin Ustun; Masumi Ueda Oshima; Geoffrey L Uy; Edmund K Waller; Sumithira Vasu; Melhem Solh; Asmita Mishra; Lori S Muffly; Hee-Je Kim; Matthias Stelljes; Yuho Najima; Masahiro Onozawa; Kirsty Thomson; Caroline Chen; Nahla Hasabou; Matt Rosales; Jason E Hill; Stanley C Gill; Rishita Nuthethi; Denise King; Adam Mendizabal; Steven M Devine; Mary M Horowitz; Yi-Bin Chen
    Blood advances, 9, 20, 5123, 5133, 2025年10月28日, [国際誌]
    英語, 研究論文(学術雑誌), We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT), focusing the interactions between conditioning regimen intensity, measurable residual disease (MRD), and NPM1 comutation status reported from diagnosis. Comparing FLT3-ITD MRD before and after conditioning, there was no difference between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in eradication or reduction of FLT3-ITD MRD. For participants who were FLT3-ITD MRD negative before HCT, there was no difference in the cumulative incidence of relapse during follow-up between those receiving MAC vs RIC. NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from post-HCT gilteritinib, and in these participants, post-HCT gilteritinib in the setting of RIC appeared to be as effective as MAC at preventing relapse. MAC appeared superior to RIC in preventing relapse only in participants who were NPM1 wild type at diagnosis and FLT3-ITD MRD positive before HCT. Our findings suggest that only a subset of patients with FLT3-ITD AML undergoing HCT may benefit from MAC and that, similar to AML therapy before HCT, the intensity of the HCT regimen should be adapted according to the molecular features of the disease. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
  • 北海道におけるCPX-351の治療成績 北海道白血病ネット
    松川 敏大; 小野澤 真弘; 長井 惇; 日高 大輔; 横山 翔大; 藤井 文彰; 吉田 匠汰; 近藤 健; 千丈 創; 小津 峻佑; 武田 紫; 関口 柚史; 清水 拓; 高橋 知希; 山本 聡; 豊嶋 崇徳
    日本血液学会学術集会, 87回, O3, 6, (一社)日本血液学会, 2025年10月
    英語
  • Asphyxiation due to obstructive fibrinous tracheal pseudomembrane after closure of repeated tracheostomy in a case of von Recklinghausen disease
    Taiki Hara; Ken Enda; Taku Maeda; Yohei Ikebe; Hideki Ujiie; Masahiro Onozawa
    Respiratory Medicine Case Reports, 102298, 102298, Elsevier BV, 2025年09月
    研究論文(学術雑誌)
  • An Autopsy Case of Amyotrophic Lateral Sclerosis With Sudden Death Showed Histological Features of Lewy Body Disease.
    Shunsuke Miyachi; Yuki Oshima; Kazuo Yazaki; Nozomi Futaki; Yusuke Shirai; Zen-Ichi Tanei; Yohei Ikebe; Ikuko Iwata; Hideki Ujiie; Masahiro Onozawa; Satoshi Hirano; Shinya Tanaka; Ichiro Yabe
    Neuropathology : official journal of the Japanese Society of Neuropathology, 45, 4, e70009, 2025年08月, [国際誌]
    英語, 研究論文(学術雑誌), We present the case of an 81-year-old man diagnosed with probable amyotrophic lateral sclerosis (ALS) based on the Updated Awaji criteria. The patient exhibited progressive motor neuron degeneration with muscle weakness, atrophy, and fasciculations primarily in the right lower limb and later extending to the right upper limb. Three months after being referred to a home care clinic, he collapsed in front of his family members and died. An autopsy revealed phosphorylated TDP-43 pathology consistent with ALS, with involvement of the hypoglossal nucleus, facial nerve nucleus, and medulla oblongata. Interestingly, widespread a-synuclein pathology indicative of diffuse neocortical type Lewy body disease (LBD; Braak stage 6) was identified, despite the absence of clinical parkinsonism or dementia with Lewy bodies (DLB) during his lifetime. The presence of autonomic symptoms such as constipation and urinary retention shortly before death may be attributable to a-synuclein pathology affecting the autonomic nervous system. The coexistence of ALS and LBD underscores the clinical challenge of diagnosing overlapping pathologies, as motor symptoms may obscure signs of LBD. Dopamine transporter imaging or MIBG myocardial scintigraphy might aid in identifying preclinical LBD in ALS patients with atypical symptoms. The patient died of respiratory failure due to extensive organizing pneumonia, but the possibility of sudden cardiac arrest could not be excluded. This case highlights the potential for coexisting neurodegenerative pathologies in ALS, emphasizing the importance of comprehensive evaluation when autonomic symptoms or other atypical features are present.
  • Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.
    Minoru Kanaya; Masahiro Onozawa; Toshihiro Matsukawa; Naoki Miyashita; Fumiaki Fujii; Shota Yoshida; Jun Nagai; Masayuki Aiba; Daisuke Hidaka; Junichi Hashiguchi; Hajime Senjo; Tetsuyuki Igarashi; Masahiro Chiba; Satoshi Yamamoto; Taku Shimizu; Takashi Ishio; Shota Yokoyama; Ko Ebata; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
    Blood cancer journal, 15, 1, 118, 118, 2025年07月03日, [国際誌]
    英語
  • Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.
    Hideki Makishima; Taisuke Mikasa; Kento Isogaya; Toshihiro Miyamoto; Takuji Yamauchi; Akira Yokota; Masahiro Onozawa; Kiyoshi Ando; Yoshiaki Ogawa; Kensuke Usuki; Takahiro Yamauchi; Shuichi Ota; Satoru Takada; Yasuyoshi Morita; Takayuki Ishikawa; Katsuto Takenaka; Junya Kuroda; Naohiro Sekiguchi; Toshiro Kawakita; Yasushi Miyazaki
    International journal of hematology, 122, 1, 57, 65, 2025年07月, [国内誌]
    英語, 研究論文(学術雑誌), This phase 1/2 study investigated the association between genetic characteristics and outcomes for NS-87/CPX-351 in Japanese patients with high-risk acute myeloid leukemia. Blood samples collected from 29 patients were analyzed using a 70-gene next-generation sequencing panel. The most frequently mutated genes were TP53 (44.8%), TET2 (24.1%), DNMT3A (13.8%), and NRAS (13.8%). The rates of composite complete remission (CRc; complete remission [CR] or CR with incomplete hematologic recovery [CRi]) were comparable between patients with and without mutations in TP53, TET2, DNMT3A, and NRAS (P = 0.571 for all). Notably, patients with TP53 mutations had a similar CRc rate (69.2% vs. 56.3%), but shorter overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) compared to patients with wild-type TP53 (median OS: 7.43 vs. 18.18 months; P = 0.108, median EFS: 2.43 vs. 6.28 months; P = 0.012, median RFS: 1.48 vs. 10.19 months; P = 0.012). In conclusion, no gene mutations directly associated with the efficacy of NS-87/CPX-351 were found. While NS-87/CPX-351 achieved remission even in patients with TP53 mutations, relapse risk was higher in these patients. Therefore, it is advisable to consider treatment strategies such as early transplantation after achieving remission with NS-87/CPX-351, especially in patients with TP53 mutations.
  • Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
    Shota Yoshida; Masahiro Onozawa; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Shinsuke Hirabayashi; Takeshi Kondo; Daigo Hashimoto; Yasuhito Onodera; Takanori Teshima
    Experimental hematology, 149, 104819, 104819, 2025年05月31日, [国際誌]
    英語, 研究論文(学術雑誌), Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is the most frequent gene mutation in acute myeloid leukemia. The consequences of FLT3-ITD have been analyzed in detail; however, the molecular mechanisms underlying the generation of FLT3-ITD remain to be elucidated. We analyzed FLT3-ITDs in clinical samples using deep sequencing and identified not only oligoclonal ITDs but also rare deletion clones clustered at the palindrome-like sequence at FLT3 exon 14. We hypothesized that FLT3 exon 14 is genetically unstable due to the palindrome-like sequence at the region and that genomic damage at the site initiates FLT3-ITD formation. We used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 to induce DNA damage for creating artificial FLT3-ITDs in human and mouse cell lines. We found that double nicks on the adjacent contralateral strand most efficiently generate ITDs. The artificial ITDs resembled clinical ITDs in the length distribution and characteristics at the joint. We further compared the inhibitory effects of olaparib and peposertib, specific inhibitors of single-strand break (SSB) and double-strand break (DSB) repair, respectively. Peposertib remarkably reduced ITD formation, but olaparib did not affect the mutation pattern. The findings indicated that nonhomologous end joining has a crucial role in the generation of ITDs. Our data shed light to the new role of peposertib, which potentially suppresses the generation of de novo FLT3-ITDs caused by mis-repair events of the DNA damages in a clinical course.
  • Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
    Mark J Levis; Mehdi Hamadani; Brent R Logan; Richard J Jones; Anurag K Singh; Mark R Litzow; John R Wingard; Esperanza B Papadopoulos; Alexander E Perl; Robert J Soiffer; Celalettin Ustun; Masumi Ueda Oshima; Geoffrey L Uy; Edmund K Waller; Sumithira Vasu; Melhem Solh; Asmita Mishra; Lori S Muffly; Hee-Je Kim; Matthias Stelljes; Yuho Najima; Masahiro Onozawa; Kirsty Thomson; Arnon Nagler; Andrew H Wei; Guido Marcucci; Caroline Chen; Nahla Hasabou; Matt Rosales; Jason Hill; Stanley C Gill; Rishita Nuthethi; Denise King; Adam Mendizabal; Steven M Devine; Mary M Horowitz; Yi-Bin Chen
    Blood, 145, 19, 2138, 2148, 2025年05月08日, [国際誌]
    英語, 研究論文(学術雑誌), BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 ("MORPHO") was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD-mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
  • CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway.
    Naoki Miyashita; Masahiro Onozawa; Kohei Kasahara; Toshihiro Matsukawa; Yasuhito Onodera; Kohjin Suzuki; Tomoiku Takaku; Takanori Teshima; Takeshi Kondo
    Cancer science, 2025年02月04日, [国際誌]
    英語, 研究論文(学術雑誌), In this study, the mechanisms of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) were investigated focusing additional sex combs-like 1 (ASXL1) gene mutations and their downstream effects. While TKIs have improved the prognosis of CML, some patients have shown resistant to therapy. Cases with mutations in epigenome-related genes such as ASXL1 are known to have a poor prognosis, but the underlying mechanisms of the poor prognosis are unclear. We showed that mutated ASXL1 reduces TKI sensitivity in CML cell lines, and RNA microarray analysis revealed that arachidonate 5-lipoxygenase (ALOX5) is a significantly upregulated gene under the conditional expression of mutated ASXL1. Enforced ALOX5 expression induced TKI resistance, while ALOX5 knockout increased TKI sensitivity. ALOX5 downstream signal inhibition by LY293111, a leukotriene B4 receptor (BLTR) antagonist, suppressed AKT phosphorylation and enhanced TKI sensitivity. This study revealed that TKI resistance in CML with ASXL1 mutation was induced via ALOX5 overexpression. ASXL1 mutations may confer a clonal advantage through activation of the AKT pathway following ALOX5 overexpression. While combined use of LY293111 with TKIs and asciminib showed synergistic effects against CML cells, the ALOX5-BLTR signaling pathway is novel therapeutic target for CML patients with mutated ASXL1.
  • Chronic graft-versus-host disease myelitis successfully treated with rituximab.
    Emi Yokoyama; Yuta Hasegawa; Kentaro Wakaki; Touma Suzuki; Sayaka Kajikawa; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Jun Nagai; Tomoe Ichiki; Ryo Kikuchi; Satomi Okada; Hiroyuki Ohigashi; Hideki Goto; Masahiro Onozawa; Daigo Hashimoto; Akio Mori; Takanori Teshima; Takeshi Kondo
    International journal of hematology, 2025年01月31日, [国内誌]
    英語, 研究論文(学術雑誌), Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and are difficult to diagnose. CNS manifestations of cGVHD were discussed in the 2020 National Institutes of Health cGVHD Consensus Project as one of the "atypical cGVHD manifestations" with involvement of various organ systems other than classical cGVHD organs. We experienced a case of myelitis after allo-HSCT diagnosed as cGVHD of the CNS. The neurological symptoms progressed after corticosteroid pulse therapy, resulting in severe paralysis and paresthesia of the lower extremities. The clinical course and magnetic resonance imaging findings showed some similarities with multiple sclerosis. We decided to use rituximab after the patient became refractory to corticosteroids because rituximab has been reported to be effective in multiple sclerosis by suppressing B cells on both sides of the blood-brain barrier. Rituximab was effective for the neurologic symptoms in our case. In atypical cGVHD, treatments used in corresponding autoimmune diseases may be reasonable and effective.
  • 橋中心に脳MRI T2WI高信号を呈した超高腫瘍量CD5陽性びまん性大細胞型B細胞リンパ腫
    鈴木 かなん; 原田 晋平; 杉村 駿介; 三木 康祐; 長谷川 裕太; 安本 篤史; 後藤 秀樹; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳
    臨床血液, 65, 12, 1490, 1490, (一社)日本血液学会-東京事務局, 2024年12月
    日本語
  • FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
    Toshihiro Matsukawa; Masahiro Onozawa; Takeshi Kondo; Minoru Kanaya; Daisuke Hidaka; Shuichi Ota; Akio Mori; Akio Shigematsu; Takuto Miyagishima; Yasutaka Kakinoki; Junichi Hashiguchi; Satoshi Yamamoto; Masayo Yamamoto; Kentaro Wakasa; Mutsumi Takahata; Toshimichi Ishihara; Yoshihito Haseyama; Akihito Fujimi; Tetsuya Igarashi; Takehiro Sarashina; Satoshi Iyama; Ryoji Kobayashi; Hajime Sakai; Katsuya Fujimoto; Junki Inamura; Yuji Kanisawa; Shinsuke Hirabayashi; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Annals of hematology, 103, 12, 5333, 5340, 2024年12月, [国際誌]
    英語, 研究論文(学術雑誌), Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting. We retrospectively analyzed 139 patients with FLT3-ITD-positive AML between 2012 and 2021. The median age was 63 years. In the propensity score-matched cohort, FLT3 inhibitors improved overall survival (OS) compared with patients treated without FLT3 inhibitors (3-year OS: 33.7% vs. 25.8%, p = 0.021). Patients who underwent HCT had superior outcomes to those without HCT (3-year OS: 45.3% vs. 2.2%, p < 0.0001). The combination of FLT3 inhibitors and HCT resulted in the highest OS and relapse-free survival (RFS) rates (3-year OS: 62.4%; 3-year RFS: 44.4%). Disease status before transplantation did not predict the prognosis, but use of FLT3 inhibitors increased survival in patients without complete remission before HCT. These results demonstrate the clinical impact of FLT3 inhibitors on survival outcomes in patients with FLT3-ITD-positive AML, particularly when combined with HCT. FLT3 inhibitors can improve the prognosis of AML with FLT3 mutations, especially in patients who undergo HCT.
  • Ph染色体陰性BCR::ABL1陽性急性白血病の頻度と臨床的特徴
    横山 翔大; 小野澤 真弘; 木村 弘幸; 荒 隆英; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 盛 暁生; 日高 大輔; 橋口 淳一; 若狭 健太郎; 井端 淳; 武田 紫; 重松 明男; 山本 聡; 藤本 勝也; 堤 豊; 石原 敏道; 酒井 基; 柿木 康孝; 小宅 達郎; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O1, 1, (一社)日本血液学会, 2024年10月
    英語
  • ベネトクラクスによる治療を受けた新規診断急性骨髄性白血病の遺伝子変異と予後
    宮下 直樹; 小野澤 真弘; 長井 惇; 吉田 匠汰; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 日高 大輔; 小笠原 励起; 盛 暁生; 近藤 健; 柿木 康孝; 重松 明男; 若狭 健太郎; 笠原 郁美; 石原 敏道; 橋口 淳一; 武田 紫; 石尾 崇; 酒井 基; 堤 豊; 藤本 勝也; 井山 諭; 小宅 達郎; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O2, 3, (一社)日本血液学会, 2024年10月
    英語
  • 成人B細胞性急性リンパ性白血病における複雑核型解析
    木村 弘幸; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 盛 暁生; 日高 大輔; 杉田 純一; 柿木 康孝; 堤 豊; 山本 聡; 重松 明男; 橋口 淳一; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 藤本 勝也; 石原 敏道; 酒井 基; 平林 真介; 小宅 達郎; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O3, 3, (一社)日本血液学会, 2024年10月
    英語
  • 化学療法によってMRDが残存したPh-like ALLに対し臍帯血移植を施行した一例
    千葉 雅尋; 千丈 創; 三木 康祐; 野島 慎悟; 森 祐斗; 長井 惇; 一木 朝絵; 松岡 里湖; 宮下 直樹; 小野澤 真弘; 柿木 康孝
    日本血液学会学術集会, 86回, P3, 10, (一社)日本血液学会, 2024年10月
    英語
  • BMT-CTN1506追加解析 移植後のGilteritinibとFLT3-ITD MRDの意義
    名島 悠峰; Levis Mark; 小野澤 真弘; Logan Brent; Singh Anurag K.; Papadopoulos Esperanza B.; Perl Alexander E.; Uy Geoffrey L.; Waller Edmund K.; Soiffer Robert J.; Ueda Oshima Masumi; Vasu Sumithira; Solh Melhem; Mishra Asmita; Muffly Lori S.; Kim Hee Je; Stelljes Matthias; Thomson Kirsty; Nagler Amon; Wei Andrew H.; Marcucci Guido; Hasabou Nahla; Chen Caroline; Rosales Matt; Hill Jason; Gill Stanley C.; Nuthethi Rishita; Hamadani Mehdi; Horowitz Mary; Chen Yi Bin
    日本血液学会学術集会, 86回, O2, 1, (一社)日本血液学会, 2024年10月
    英語
  • HLA半合致移植を施行したShwachman-Diamond症候群(SDS)を背景とした急性骨髄性白血病
    塚本 しほり; 中川 雅夫; 小野澤 真弘; 南谷 泰仁; 小島 圭祐; 原田 知弥; 荒 隆英; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳
    臨床血液, 65, 10, 1329, 1329, (一社)日本血液学会-東京事務局, 2024年10月
    日本語
  • FLT3阻害薬は投与時期に関わらずFLT3変異AMLの予後を延長する
    松川 敏大; 近藤 健; 日高 大輔; 太田 秀一; 金谷 穣; 盛 暁生; 重松 明男; 宮城島 拓人; 柿木 康孝; 橋口 淳一; 山本 聡; 山本 昌代; 若狭 健太郎; 高畑 むつみ; 石原 敏道; 長谷山 美仁; 藤見 章仁; 五十嵐 哲祥; 更科 岳大; 井山 諭; 小林 良二; 酒井 基; 藤本 勝也; 稲村 純季; 蟹澤 祐司; 平林 真介; 小野澤 真弘; 遠藤 知之; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O1, 5, (一社)日本血液学会, 2024年10月
    英語
  • Ph染色体陰性BCR::ABL1陽性急性白血病の頻度と臨床的特徴
    横山 翔大; 小野澤 真弘; 木村 弘幸; 荒 隆英; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 盛 暁生; 日高 大輔; 橋口 淳一; 若狭 健太郎; 井端 淳; 武田 紫; 重松 明男; 山本 聡; 藤本 勝也; 堤 豊; 石原 敏道; 酒井 基; 柿木 康孝; 小宅 達郎; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O1, 1, (一社)日本血液学会, 2024年10月
    英語
  • ベネトクラクスによる治療を受けた新規診断急性骨髄性白血病の遺伝子変異と予後
    宮下 直樹; 小野澤 真弘; 長井 惇; 吉田 匠汰; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 日高 大輔; 小笠原 励起; 盛 暁生; 近藤 健; 柿木 康孝; 重松 明男; 若狭 健太郎; 笠原 郁美; 石原 敏道; 橋口 淳一; 武田 紫; 石尾 崇; 酒井 基; 堤 豊; 藤本 勝也; 井山 諭; 小宅 達郎; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O2, 3, (一社)日本血液学会, 2024年10月
    英語
  • 成人B細胞性急性リンパ性白血病における複雑核型解析
    木村 弘幸; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 盛 暁生; 日高 大輔; 杉田 純一; 柿木 康孝; 堤 豊; 山本 聡; 重松 明男; 橋口 淳一; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 藤本 勝也; 石原 敏道; 酒井 基; 平林 真介; 小宅 達郎; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 86回, O3, 3, (一社)日本血液学会, 2024年10月
    英語
  • Novel CAR T cell therapies for patients with large B cell lymphoma.
    Hideki Goto; Masahiro Onozawa; Takanori Teshima
    International journal of hematology, 2024年05月25日, [国内誌]
    英語, 研究論文(学術雑誌), Approximately 60-70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients who relapse or are refractory to initial treatment have a poor prognosis. Chimeric antigen receptor (CAR) T cell therapy has recently attracted attention for its potential to provide a cure or long-term remission even for LBCL that has relapsed or is refractory to conventional chemotherapy. Currently, three CAR T cell products are clinically available for LBCL: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel). These CAR T cell products were initially approved as third- or later-line therapies worldwide. Recently, axi-cel and liso-cel have become feasible as second-line therapies for patients with early relapsed or refractory disease after first-line chemotherapy. Although a large body of data on CAR T cell therapy has been accumulated, the clinical question of how to choose between these three available CAR T cell products has yet to be resolved. The appropriate approach to treatment selection for patients who relapse after CAR T cell therapy also remains unclear. This review discusses treatment strategies to maximize the benefits of CAR T cell therapy.
  • Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
    Mark J Levis; Mehdi Hamadani; Brent Logan; Richard J Jones; Anurag K Singh; Mark Litzow; John R Wingard; Esperanza B Papadopoulos; Alexander E Perl; Robert J Soiffer; Celalettin Ustun; Masumi Ueda Oshima; Geoffrey L Uy; Edmund K Waller; Sumithra Vasu; Melhem Solh; Asmita Mishra; Lori Muffly; Hee-Je Kim; Jan-Henrik Mikesch; Yuho Najima; Masahiro Onozawa; Kirsty Thomson; Arnon Nagler; Andrew H Wei; Guido Marcucci; Nancy L Geller; Nahla Hasabou; David Delgado; Matt Rosales; Jason Hill; Stanley C Gill; Rishita Nuthethi; Denise King; Heather Wittsack; Adam Mendizabal; Steven M Devine; Mary M Horowitz; Yi-Bin Chen
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42, 15, 1766, 1775, 2024年05月20日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS: Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS: Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.
  • Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review.
    Naoki Kosaka; Takanori Uchiyama; Masahiro Onozawa; Jun Nagai; Jiro Koya; Suguru Ishizaka; Toshiyuki Nagai; Yohei Ikebe; Kenjiro Kato; Zen-Ichi Tanei; Jun Sakakibara-Konishi; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Hideki Ujiie; Satoshi Hirano; Satoshi Konno; Toshihisa Anzai; Koji Taniguchi; Shinya Tanaka; Takanori Teshima
    Internal medicine (Tokyo, Japan), 2024年04月16日, [国内誌]
    英語, 研究論文(学術雑誌), We herein present a fatal case of constrictive pericarditis (CP) due to acute myelomonocytic leukemia (AMML) in a patient who initially complained of an acute onset of chest pain two days after COVID-19 vaccination. An autopsy revealed pericardial infiltration of leukemic cells. CP is rarely associated with leukemia and only 14 cases have been reported in the literature. The etiology of CP in previous reports included leukemic infiltration, graft-versus-host disease, drug-induced, post-radiation, autoimmune, and otherwise unidentified. This case indicates that leukemic infiltration can cause CP and that clinicians should include leukemia in the differential diagnosis of CP.
  • A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Kensuke Usuki; Toshihiro Miyamoto; Takuji Yamauchi; Kiyoshi Ando; Yoshiaki Ogawa; Masahiro Onozawa; Takahiro Yamauchi; Hitoshi Kiyoi; Akira Yokota; Takayuki Ikezoe; Yuna Katsuoka; Satoru Takada; Nobuyuki Aotsuka; Yasuyoshi Morita; Takayuki Ishikawa; Noboru Asada; Shuichi Ota; Atsushi Dohi; Kensaku Morimoto; Shunji Imai; Umi Kishimoto; Koichi Akashi; Yasushi Miyazaki
    International journal of hematology, 2024年03月26日, [国内誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: NS-87/CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin. NS-87/CPX-351 exerts antileukemic action by maintaining a synergistic molar ratio of cytarabine to daunorubicin of 5:1 within the liposome while in circulation. Patients with high-risk acute myeloid leukemia (AML), which includes therapy-related AML and AML with myelodysplasia-related changes (AML-MRC), have poorer outcomes than those with other AML. METHODOLOGY: This open-label phase 1/2 (P1/2) study was conducted in 47 Japanese patients aged 60-75 years with newly diagnosed high-risk AML to evaluate the pharmacokinetics, safety, and efficacy of NS-87/CPX-351. RESULTS: In the 6 patients enrolled in the P1 portion, no dose-limiting toxicities (DLTs) were reported, and 100 units/m2 during the induction cycle was found to be acceptable. Cytarabine and daunorubicin had a long half-life in the terminal phase (32.8 and 28.7 h, respectively). In the 35 patients enrolled in the P2 portion, composite complete remission (CRc; defined as complete remission [CR] or CR with incomplete hematologic recovery [CRi]) was achieved in 60.0% (90% CI: 44.7-74.0) of the patients. Adverse events due to NS-87/CPX-351 were well tolerated. OUTCOMES: NS-87/CPX-351 can be considered as a frontline treatment option for Japanese patients with high-risk AML.
  • Relative impact of THPO mutation causing hereditary thrombocythemia.
    Hiroyuki Kimura; Masahiro Onozawa; Toshihiro Matsukawa; Hideki Goto; Takeshi Kondo; Takanori Teshima
    Experimental hematology, 104208, 104208, 2024年03月26日, [国際誌]
    英語, 研究論文(学術雑誌), Germline mutations of THPO were reported as causes of hereditary thrombocythemia. Six previously reported distinct sites of the mutation were clustered at the 5'-untranslated region or the exon 3 splicing donor site of the THPO gene. Each mutation was identified in an independent pedigree and the difference in the mutations were not compared. We cloned 6 distinct THPO mutations (THPO c.-47delG, THPO c.-31G>T, THPO c.13G>A, THPO c.13+1G>A, THPO c.13+2T>C, and THPO c.13+5G>A) and compared the molecular mechanisms that underlie the increased production of THPO protein. At the transcript level, all of the mutations except THPO c.-47delG showed an exon 3 skipping transcript including 2 mutations (THPO c.-31G>T and THPO c.13+5G>A) that were distant from the splicing donor site. THPO c.-47delG showed the same full-length transcript as that of the wild-type transcript. At the protein level, all mutations resulted in a higher level of production of THPO protein compared to wild-type THPO. There are only two distinct patterns of mechanisms for increased production of THPO: 1) exon 3 skipping that deleted upstream suppressive open reading frame (ORF) 7 and 2) one base deletion that shifted ORF7 to connect to the initial codon of THPO in-frame. The common mechanisms of hereditary thrombocytosis due to THPO mutation are unleashed THPO translation that is usually suppressed by upstream out-of-frame ORF7.
  • MYD88 L265P遺伝子変異検索を用いて診断されたリンパ形質細胞性リンパ腫の検討(Lymphoplasmacytic lymphoma diagnosed by MYD88 L265P mutation analysis of bone marrow biopsy)
    岡崎 ななせ; 清水 亜衣; 小野澤 真弘; 宮下 直樹; 高桑 恵美; 中里 信一; 杉田 純一; 岡田 耕平; 外丸 詩野; 松野 吉宏
    日本病理学会会誌, 113, 1, 447, 447, (一社)日本病理学会, 2024年02月
    英語
  • 肺小細胞癌の治療中に白血球増多と線維素性心外膜炎を認めた一例
    山内 智仁; 種井 善一; 長井 淳; 小田 義崇; 菊池 遼; 小野澤 真弘; 津田 真寿美; 田中 敏; 豊島 崇徳; 田中 伸哉
    日本病理学会会誌, 113, 1, 463, 463, (一社)日本病理学会, 2024年02月
    日本語
  • Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Naoki Miyashita; Masahiro Onozawa; Toshihiro Matsukawa; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Kentaro Wakasa; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
    British journal of haematology, 2024年01月18日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Impact of the Covid-19 pandemic and ensuing online teaching on pre-clinical medical education.
    Houman Goudarzi; Masahiro Onozawa; Makoto Takahashi
    BMC medical education, 24, 1, 66, 66, 2024年01月17日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Major disruptions and changes in education have occurred worldwide as a result of the coronavirus disease (COVID-19) pandemic and the ensuing shift from in-person to online education. However, the effect of such changes on medical education, its magnitude, and the learning domains impacted by such rapid changes have not been adequately addressed, particularly with regard to objective assessment approaches. METHODS: Second-year medical students enrolled in our Medical English Course between 2019 and 2021 were recruited from Hokkaido University, Japan (N = 321) to participate in this study. We evaluated the potential impact of teaching styles on the academic performance of students before (2019; face-to-face) and during (2020; online; 2021; in-person and online) the pandemic. We examined the potential effect of three teaching styles--in-person (2019), online (2020), and a combination of these (2021) on the academic performance of medical students using: (i) subjective assessment of self-reported general English skills, including reading, writing, listening, and speaking; and (ii) objective assessment of medical terminology scores, evidence-based medicine (EBM) skills, and final written exam scores. RESULTS: In-person education significantly improved listening and speaking skills in 2019 (p < 0.001). This trend was observed for writing skills in an online course in 2020 (p = 0.001). With the combined teaching method, students reported significant improvements in all four English skills. In our objective assessments, medical terminology improved significantly post-test versus pre-test for all three teaching styles, and we found that the online course did not adversely affect the gain in medical terminology knowledge during the course. Additionally, we did not find any significant differences across the three applied teaching styles regarding EBM skill levels. It is noteworthy that the students taking online courses had a significantly higher final exam score (mean ± SD; 82.8 ± 8.2) than in in-person (78.6 ± 8.8) and combined (79.7 ± 12.1) teaching styles. CONCLUSIONS: In our study, the online/combined courses showed better academic outcomes compared to the face-to-face course in the preclinical clerkship. Although the current results need to be replicated on a larger scale, online/combined courses can continue and evolve in the post-pandemic education of medical students. Medical schools and institutions should consider incorporating such courses, especially combined courses, into their curricula in the future to improve the effectiveness, accessibility, and flexibility of medical education.
  • Outcomes of cessation of the administration of nucleos(t)ide analogues on HBV reactivation after allogeneic hematopoietic stem cell transplantation: A nationwide retrospective study.
    Masahiro Onozawa; Shigeru Kusumoto; Yuho Najima; Hiroya Hashimoto; Kohei Okada; Masaharu Tamaki; Masatsugu Tanaka; Takayuki Sato; Tsutomu Takahashi; Kaoru Hatano; Koichi Onodera; Yukiyoshi Moriuchi; Kimikazu Yakushijin; Junya Kanda; Koji Nagafuji; Masao Ogata; Nobuaki Nakano; Akihiro Tamori; Masashi Mizokami
    Transplantation and cellular therapy, 2024年01月17日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Monitoring of HBV-DNA and HBV-DNA-guided preemptive therapy using nucleos(t)ide analogues (NAs) are recommended for preventing the development of hepatitis due to HBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recipients with resolved HBV infection. However, little is known about the appropriate duration of NA treatment and the outcomes of NAs cessation on recurrence of HBV reactivation. OBJECTIVE: To clarify the consequences of NAs cessation in recipients with resolved HBV infection who experienced HBV reactivation following allo-HSCT. STUDY DESIGN: We retrospectively reviewed the clinical records of recipients with resolved HBV infection (HBsAg-negative, anti-HBc-positive) before allo-HSCT who had been diagnosed as having HBV reactivation (HBsAg-positive and/or HBV-DNA detectable) after allo-HSCT during the period from January 2010 to December 2020. RESULTS: A total of 72 patients from 16 institutes were registered (median age of the patients, 60 years; age range, 27-73 years; 42 males and 30 females). Initial HBV reactivation was observed on day 10 to day 3034 (median, 513 days) after allo-HSCT. Anti-HBs were lost in more than 80% of the patients at the time of HBV reactivation. All 72 patients received preemptive NAs and no fatal HBV reactivation-related hepatitis was observed. There was continuous detection of HBV-DNA without hepatitis in 5 patients during the follow-up period. Administration of NAs was discontinued in 24 (33%) of 72 patients by each physician's decision. Second HBV reactivation occurred in 11 (46%) of the 24 patients in whom administration of NAs was discontinued. Duration of NA treatment were not significantly different between patients with or without second HBV reactivation. The frequency of further HBV reactivation tended to be lower in patients with anti-HBs titer of more than 10 mIU/mL at the time of NA cessation. CONCLUSION: Multiple reactivation of HBV after NA discontinuation was common in patients with HBV reactivation who received allo-HSCT despite the long duration of NA. Careful monitoring of HBV-DNA is important even after the discontinuation of NA in the case with HBV reactivation after allo-HSCT because multiple reactivations could occur. Active immunization by HB vaccine might be effective for suppressing further HBV reactivation after cessation of NAs.
  • Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family.
    Hiroyuki Kimura; Masahiro Onozawa; Junichi Hashiguchi; Daisuke Hidaka; Minoru Kanaya; Toshihiro Matsukawa; Hiromi Okada; Takeshi Kondo; Yoshihiro Matsuno; Takanori Teshima
    Annals of hematology, 103, 1, 89, 96, 2024年01月, [国際誌]
    英語, 研究論文(学術雑誌), Thrombopoietin (THPO) is an essential factor for platelet production. Hereditary thrombocythemia (HT) is caused by a germline mutation of THPO, MPL, or JAK2 and is inherited in an autosomal-dominant manner. We identified a Japanese family with HT due to a point mutation of the splicing donor site of the THPO gene (THPO c.13 + 1G > A). Bone marrow biopsy showed increased megakaryocytes mimicking essential thrombocythemia. One affected family member developed chronic myeloid leukemia. We cloned the mutation and developed mutated and wild type THPO expression vectors. Molecular analysis showed that the mutation causes an exon 3 skipping transcript of THPO that abrogates a suppressive untranslated upstream open reading frame. Although the transcript levels of THPO mRNA were comparable, mutated transcripts were more efficiently translated and THPO protein expression was significantly higher than that of the wild type.
  • Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans.
    Hiroyuki Kimura; Masahiro Onozawa; Takanori Teshima
    Platelets, 34, 1, 2276697, 2276697, 2023年12月, [国際誌]
    英語, 研究論文(学術雑誌)
  • 再発難治性びまん性大細胞型B細胞リンパ腫に対するCAR-T細胞療法後にpseudo-progressionを認めた1例
    藤井 文彰; 千葉 雅尋; 橋田 里妙; 長谷川 祐太; 大東 寛幸; 安本 篤史; 後藤 秀樹; 山口 圭介; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳
    臨床血液, 64, 12, 1523, 1524, (一社)日本血液学会-東京事務局, 2023年12月
    日本語
  • CD10陽性のIgG型リンパ形質細胞性リンパ腫の1例
    金谷 穣; 種井 善一; 宮下 直樹; 一木 朝絵; 梶川 清芽; 横山 絵美; 泉山 康; 斎藤 誠; 森岡 正信; 盛 暁生; 関 真秀; 辻 隆裕; 大島 孝一; 小野澤 真弘; 田中 伸哉; 近藤 健
    臨床血液, 64, 12, 1525, 1525, (一社)日本血液学会-東京事務局, 2023年12月
    日本語
  • 移植前WT1は急性骨髄性白血病における予後因子となる
    松川 敏大; 小野澤 真弘; 日高 大輔; 長井 惇; 吉田 匠汰; 宮下 直樹; 木村 弘幸; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 266, 266, (一社)日本血液学会, 2023年10月
    英語
  • 初発AMLに対するベネトクラックス投与日数短縮Ven-Aza療法 北海道白血病ネットによる後方視的解析
    金谷 穣; 小野澤 真弘; 宮下 直樹; 松川 敏大; 横山 翔大; 吉田 匠汰; 木村 弘幸; 長井 惇; 相庭 昌之; 杉村 駿介; 野津 麟太郎; 藤井 文彰; 江端 浩; 井端 淳; 伊吹 紗央莉; 小宅 達郎; 清水 拓; 山本 聡; 重松 明男; 五十嵐 哲祥; 橋口 淳一; 日高 大輔; 盛 暁生; 近藤 健; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 374, 374, (一社)日本血液学会, 2023年10月
    英語
  • 臨床的FLT3-ITD陰性AMLにおける微小FLT3-ITDクローン
    横山 翔大; 小野澤 真弘; 吉田 匠汰; 宮下 直樹; 木村 弘幸; 高橋 承吾; 松川 敏大; 後藤 秀樹; 藤澤 真一; 三木 康祐; 日高 大輔; 橋口 淳一; 若狭 健太郎; 井端 淳; 武田 紫; 重松 明男; 藤本 勝也; 堤 豊; 盛 暁生; 石原 敏道; 柿木 康孝; 近藤 健; 橋本 大吾; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 269, 269, (一社)日本血液学会, 2023年10月
    英語
  • 新規発症の急性リンパ性白血病におけるWT1
    松川 敏大; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 木村 弘幸; 金谷 穣; 太田 秀一; 盛 暁生; 近藤 健; 柿木 康孝; 皆内 康一郎; 重松 明男; 若狭 健太郎; 橋口 淳一; 石原 敏道; 藤本 勝也; 堤 豊; 井端 淳; 酒井 基; 小宅 達郎; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 395, 395, (一社)日本血液学会, 2023年10月
    英語
  • Dominant-negativeタイプのIKZF1欠失が成人B細胞性急性リンパ性白血病に与える影響
    木村 弘幸; 小野澤 真弘; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 後藤 秀樹; 小栗 聡; 藤澤 真一; 盛 暁生; 近藤 健; 日高 大輔; 岡田 耕平; 太田 秀一; 柿木 康孝; 堤 豊; 山本 聡; 宮城島 拓人; 橋口 淳一; 永嶋 貴博; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 高橋 承吾; 藤本 勝也; 石原 敏道; 酒井 基; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 1095, 1095, (一社)日本血液学会, 2023年10月
    英語
  • NPM1変異陽性急性骨髄性白血病におけるDNMT3A R882変異の臨床的意義
    宮下 直樹; 小野澤 真弘; 吉田 匠汰; 長井 惇; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 小笠原 励起; 日高 大輔; 盛 暁生; 近藤 健; 松岡 里湖; 重松 明男; 若狭 健太郎; 笠原 郁美; 佐賀 智之; 橋口 淳一; 武田 紫; 井端 淳; 堤 豊; 藤本 勝也; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 1222, 1222, (一社)日本血液学会, 2023年10月
    英語
  • 悪性リンパ腫へのtisagenlecleucelの治療効果に関するPET/CTで評価されたMTHとDmaxのインパクト
    後藤 秀樹; 北脇 年雄; 加藤 光次; 藤井 伸治; 大西 康; 福原 規子; 山内 拓司; 虎谷 和則; 下茂 雅俊; 小林 宏紀; 小野寺 晃一; 吉田 匠汰; 千丈 創; 小野澤 真弘; 平田 健司; 横田 勲; 豊嶋 崇徳
    日本血液学会学術集会, 85回, 1193, 1193, (一社)日本血液学会, 2023年10月
    英語
  • Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
    Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Bone marrow transplantation, 2023年09月05日, [国際誌]
    英語
  • Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
    Hiroyuki Kimura; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Hideki Goto; Tomoyuki Endo; Satoshi Oguri; Shinichi Fujisawa; Akio Mori; Takeshi Kondo; Daisuke Hidaka; Kohei Okada; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Junichi Hashiguchi; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takanori Teshima
    Annals of hematology, 2023年08月19日, [国際誌]
    英語, 研究論文(学術雑誌), IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each deletion has not been fully elucidated. We retrospectively analyzed 117 patients with adult B-ALL including 60 patients with BCR::ABL1-positive B-ALL and 57 patients with BCR::ABL1-negative B-ALL by the fluorescence in situ hybridization (FISH) method for IKZF1 deletion and multiplex PCR for the 4 most common IKZF1 deletions (∆4-7, ∆2-7, ∆2-8, and ∆4-8). Samples, in which IKZF1 deletion was detected by FISH but a specific type of deletion was not identified by the PCR, were categorized as "other." Patients were classified into a DN group that had at least 1 allele of ∆4-7 (n = 23), LOF and other group (n = 40), and wildtype group (n = 54). DN type IKZF1 deletions were found in 33.3% of BCR::ABL1-positive cases and 5.2% of BCR::ABL1-negative cases. LOF and other type IKZF1 deletions were found in 43.4% of BCR::ABL1-positive cases and 24.6% of BCR::ABL1-negative cases. Patients with the DN group showed significantly higher overall survival (OS) than that of the LOF and other and WT groups (P = 0.011). Multivariate analysis including age, WBC counts, complex karyotype, and DN type IKZF1 deletion showed that the DN type of IKZF1 deletion (HR = 0.22, P = 0.013) had a positive impact and age ≥ 65 (HR = 1.92, P = 0.029) had a negative impact on OS. The prognostic impact of IKZF1 deletion depends on the type of deletion and DN type of IKZF1 deletion showed better prognosis in adult B-ALL patients.Clinical trial registration This study was part of a prospective observational study (Hokkaido Leukemia Net, UMIN000048611). It was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Hokkaido University Hospital (#015-0344).
  • Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.
    Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    Cancer medicine, 12, 16, 16881, 16888, 2023年08月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: We have reported that seroconversion rates after the second dose of mRNA-based COVID-19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited data for the response to a third vaccine dose in those patients. AIMS: In this complementary study, we investigated the booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies. MATERIALS & METHODS: A total 58 patients including 20 patients with MDS and 38 patients with AML were enrolled. Anti-SARS-CoV-2S immunoassays were performed at 3, 6, and 9 months after the second vaccine dose. RESULTS: Seventy-five percent of the MDS patients and 37% of the AML patients were receiving active treatment at the time of the third vaccination. Both the initial and third vaccine response in AML patients were comparable to those in HCs. In MDS patients, although the initial vaccine immunogenicity was inferior to that in HCs and AML patients, the third vaccine improved the response to a level not inferior to those in HCs and AML patients. Of note, the third vaccine resulted in a significant increase of antibodies in actively treated MDS patients who had shown a response inferior to that in untreated patients after two doses of vaccination. DISCUSSION: In patients with myeloid malignancies, the third vaccine dose showed a booster effect, and disease- and therapy-related factors associated with the booster response have been identified. CONCLUSION: The third dose of an mRNA-based COVID-19 vaccine showed a booster effect in patients with myeloid malignancies. Such a good booster response has not been reported in other haematological malignancies.
  • Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Toru Miyajima; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Junichi Sugita; Shinichi Fujisawa; Daisuke Hidaka; Reiki Ogasawara; Akio Mori; Satomi Matsuoka; Akio Shigematsu; Kentaro Wakasa; Ikumi Kasahara; Tomoyuki Saga; Junichi Hashiguchi; Yukari Takeda; Makoto Ibata; Tsutsumi Yutaka; Katsuya Fujimoto; Takeshi Kondo; Takanori Teshima
    European journal of haematology, 2023年07月19日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The cryptic fusion oncogene NUP98::NSD1 is known to be associated with FLT3-ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in pediatric AML. However, there are little data regarding the clinical significance of NUP98::NSD1 in adult cohort. METHODS: We conducted a multicenter retrospective study to investigate the prevalence, clinical characteristics, and prognostic impact of NUP98::NSD1 in adult FLT3-ITD-positive AML patients. RESULTS: In a total of 97 FLT3-ITD-positive AML patients, six cases (6.2%) were found to harbor the NUP98::NSD1 fusion transcript. NUP98::NSD1 positive cases had significantly higher platelet counts and a higher frequency of FAB-M4 morphology than NUP98::NSD1 negative cases. NUP98::NSD1 was found to be mutually exclusive with NPM1 mutation, and was accompanied by the WT1 mutation in three of the six cases. The presence of NUP98::NSD1 fusion at the time of diagnosis predicted poor response to cytarabine-anthracycline-based intensive induction chemotherapy (induction failure rate: 83% vs. 36%, p = .038). Five of the six cases with NUP98::NSD1 underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two of the five cases have successfully maintained remission, with one of them being rescued through a second HSCT. CONCLUSIONS: Detecting NUP98::NSD1 in adult FLT3-ITD-positive AML is crucial to recognizing chemotherapy-resistant group.
  • Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
    Ryo Kikuchi; Masahiro Onozawa; Jun Nagai; Satomi Okada; Yuta Hasegawa; Hiroyuki Ohigashi; Shintaro Mitamura; Taku Maeda; Emi Takakuwa; Yuichiro Fujieda; Hideki Goto; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
    Internal medicine (Tokyo, Japan), 2023年06月14日, [国内誌]
    英語, 研究論文(学術雑誌), Cryoglobulins are immunoglobulins that precipitate in cold conditions. Type I cryoglobulinemic vasculitis is associated with hematological malignancies. We herein report a case of steroid-resistant type 1 cryoglobulinemic vasculitis associated with monoclonal gammopathy of undetermined significance (MGUS) in a 47-year-old woman. By immunofixation of cryoglobulin, we found that the main component of cryoglobulin was the M protein due to MGUS, so treatment of MGUS was needed. Bortezomib+dexamethasone therapy resulted in a rapid decrease in cryoglobulin and improvement in the symptoms of cryoglobulinemic vasculitis. In refractory type I cryoglobulinemic vasculitis, treatment of the underlying gammaglobulinopathy should be considered.
  • Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
    Hajime Senjo; Shinpei Harada; Shimpei I Kubota; Yuki Tanaka; Takahiro Tateno; Zixuan Zhang; Satomi Okada; Xuanzhong Chen; Ryo Kikuchi; Naoki Miyashita; Masahiro Onozawa; Hideki Goto; Tomoyuki Endo; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Yoshinori Hasegawa; Masaaki Murakami; Takanori Teshima; Daigo Hashimoto
    Blood, 2023年05月22日, [国際誌]
    英語, 研究論文(学術雑誌), Calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal-Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory-Tex), expressing both inhibitory receptors and effector molecules, into terminal-Tex, and inhibited tolerance induction. Adoptive transfer of transitory-Tex, but not terminal-Tex, into secondary recipients developed chronic GVHD. Transitory-Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory-Tex, not terminal-Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse.
  • Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
    Hideki Goto; Toshio Kitawaki; Nobuharu Fujii; Koji Kato; Yasushi Onishi; Noriko Fukuhara; Takuji Yamauchi; Kazunori Toratani; Hiroki Kobayashi; Shota Yoshida; Masatoshi Shimo; Koichi Onodera; Hajime Senjo; Masahiro Onozawa; Kenji Hirata; Isao Yokota; Takanori Teshima
    International journal of clinical oncology, 28, 6, 816, 826, 2023年04月18日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). RESULTS: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4-19.65; P < 0.05] into a high-risk group). CONCLUSION: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel.
  • Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
    Shota Yokoyama; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Toshihiro Matsukawa; Hideki Goto; Shinichi Fujisawa; Kosuke Miki; Daisuke Hidaka; Junichi Hashiguchi; Kentaro Wakasa; Makoto Ibata; Yukari Takeda; Akio Shigematsu; Katsuya Fujimoto; Yutaka Tsutsumi; Akio Mori; Toshimichi Ishihara; Yasutaka Kakinoki; Takeshi Kondo; Daigo Hashimoto; Takanori Teshima
    British journal of haematology, 201, 6, 1144, 1152, 2023年04月17日, [国際誌]
    英語, 研究論文(学術雑誌), Recent advances in next-generation sequencing (NGS) have enabled the detection of subclinical minute FLT3-ITD. We selected 74 newly diagnosed, cytogenetically normal acute myeloid leukaemia (AML) samples in which FLT3-ITD was not detected by gel electrophoresis. We sequenced them using NGS and found minute FLT3-ITDs in 19 cases. We compared cases with clinically relevant FLT3-ITD (n = 37), cases with minute FLT3-ITD (n = 19) and cases without detectable FLT3-ITD (n = 55). Molecular characteristics (location and length) of minute FLT3-ITD were similar to those of clinically relevant FLT3-ITD. Survival of cases with minute FLT3-ITD was similar to that of cases without detectable FLT3-ITD, whereas the relapse rate within 1 year after onset was significantly higher in cases with minute FLT3-ITD. We followed 18 relapsed samples of cases with clinically FLT3-ITD-negative at diagnosis. Two of 3 cases with minute FLT3-ITD relapsed with progression to clinically relevant FLT3-ITD. Two of 15 cases in which FLT3-ITD was not detected by NGS relapsed with the emergence of minute FLT3-ITD, and one of them showed progression to clinically relevant FLT3-ITD at the second relapse. We revealed the clonal dynamics of subclinical minute FLT3-ITD in clinically FLT3-ITD-negative AML. Minute FLT3-ITD at the initial AML can expand to become a dominant clone at relapse.
  • Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
    Alexander E Perl; Richard A Larson; Nikolai A Podoltsev; Stephen Strickland; Eunice S Wang; Ehab Atallah; Gary J Schiller; Giovanni Martinelli; Andreas Neubauer; Jorge Sierra; Pau Montesinos; Christian Recher; Sung-Soo Yoon; Yoshinobu Maeda; Naoko Hosono; Masahiro Onozawa; Takayasu Kato; Hee-Je Kim; Nahla Hasabou; Rishita Nuthethi; Ramon Tiu; Mark J Levis
    Transplantation and cellular therapy, 29, 4, 265.e1-265.e10, 2023年04月, [国際誌]
    英語, 研究論文(学術雑誌), The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.
  • Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.
    Mirei Kobayashi; Akio Mori; Masahiro Onozawa; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    Annals of hematology, 102, 4, 819, 827, 2023年04月, [国際誌]
    英語, 研究論文(学術雑誌), Patients with lymphoid malignancies have impaired humoral immunity caused by the disease itself and its treatment, placing them at risk for severe coronavirus disease-19 (COVID-19) and reduced response to vaccination. However, data for COVID-19 vaccine responses in patients with mature T cell and NK-cell neoplasms are very limited. In this study of 19 patients with mature T/NK-cell neoplasms, anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike antibodies were measured at 3 months, 6 months, and 9 months after the second mRNA-based vaccination. At the time of the second and third vaccinations, 31.6% and 15.4% of the patients were receiving active treatment. All patients received the primary vaccine dose and the third vaccination rate was 68.4%. In patients with mature T/NK-cell neoplasms, both seroconversion rate (p < 0.01) and antibody titers (p < 0.01) after the second vaccination were significantly lower than those in healthy controls (HC). In individuals who received the booster dose, patients had significantly lower antibody titers than those in HC (p < 0.01); however, the seroconversion rate in patients was 100%, which was the same as that in HC. The booster vaccine resulted in a significant increase of antibodies in elderly patients who had shown a response that was inferior to that in younger patients after two doses of vaccination. Since higher antibody titers and higher seroconversion rate reduced the incidence of infection and mortality, vaccination more than three times may have the advantage for patients with mature T/NK-cell neoplasms, especially in elderly patients. Clinical trial registration number: UMIN 000,045,267 (August 26th, 2021), 000,048,764 (August 26th, 2022).
  • Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.
    Maria Tada; Shion Kachi; Masahiro Onozawa; Yuichiro Fujieda; Shota Yoshida; Yotaro Oki; Kazuro Kamada; Jun Nagai; Satomi Okada; Ryo Kikuchi; Ryo Hisada; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Shinichi Nakazato; Yoshihiro Matsuno; Takanori Teshima; Tatsuya Atsumi
    Internal medicine (Tokyo, Japan), 2023年03月15日, [国内誌]
    英語, 研究論文(学術雑誌), We herein report a case of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) resembling adult-onset Still's disease (AOSD). A 40-year-old woman presented with a fever, erythema, and painful subcutaneous nodules on the trunk. Laboratory data and a bone marrow analysis showed hemophagocytic syndrome. Although AOSD was suspected, based on a histopathological evaluation of the erythema, she was diagnosed with SPTCL. She was refractory to combination chemotherapy but achieved durable remission with cyclosporine monotherapy. Genetic testing revealed a homozygous HAVCR2 c.245A>G variant (rs184868814) that had caused NLRP3 inflammasome activation. SPTCL and AOSD share a pathogenesis in terms of NLRP3 inflammasome activation, so the clinical phenotype of SPTCL reasonably mimics AOSD.
  • Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia.
    Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    British journal of haematology, 200, 6, 717, 721, 2023年03月, [国際誌]
    英語, 研究論文(学術雑誌), Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.
  • Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Naoki Miyashita; Masahiro Onozawa; Shota Yoshida; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Shinichi Fujisawa; Akio Mori; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takeshi Kondo; Takanori Teshima
    International journal of hematology, 118, 1, 36, 46, 2023年02月28日, [国内誌]
    英語, 研究論文(学術雑誌), Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.
  • Fatal case of subdural empyema caused by Campylobacter rectus and Slackia exigua
    Yuki Munekata; Saki Yamamoto; Shun Kato; Yutaro Kitagawa; Ken Enda; Nanase Okazaki; Satoshi Tanikawa; Zen Ichi Tanei; Yohei Ikebe; Takahiro Osawa; Soichiro Takamiya; Hideki Ujiie; Masahiro Onozawa; Satoshi Hirano; Miki Fujimura; Shinya Tanaka
    Autopsy and Case Reports, 13, 2023年
    研究論文(学術雑誌)
  • Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Shota Yoshida; Masahiro Onozawa; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Hajime Kobayashi; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Shuichi Ota; Takeshi Kondo; Takanori Teshima
    International journal of hematology, 117, 4, 544, 552, 2022年12月26日, [国内誌]
    英語, 研究論文(学術雑誌), Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and 17 or deletion of 5q, 7q and/or 17p) or atypical, the clinical features of these subtypes in Japanese patients remain unclear. We retrospectively analyzed a total of 115 patients with CK-AML, including 77 with typical CK-AML and 38 with atypical CK-AML. Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients without such abnormalities (105 days vs. 165 days, P = 0.033). TP53 mutations were more predominant in patients with typical CK-AML than in patients with atypical CK-AML (69.7% vs. 32.4%, P < 0.001). Patients with typical CK-AML had a poor prognosis regardless of TP53 mutation status. Among patients with atypical CK-AML, however, prognosis was worse for those with the TP53 mutation than those without the mutation. In conclusion, prognosis is extremely poor for both typical CK-AML and atypical CK-AML with TP53 mutation.
  • Future career plans of medical students and the COVID ‐19 pandemic: Time to recover?
    Houman Goudarzi; Masahiro Onozawa; Makoto Takahashi
    Journal of General and Family Medicine, Wiley, 2022年11月07日
    研究論文(学術雑誌)
  • Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
    Naoki Kawagishi; Goki Suda; Ryotaro Sakamori; Takeshi Matsui; Masahiro Onozawa; Zijian Yang; Sonoe Yoshida; Masatsugu Ohara; Megumi Kimura; Akinori Kubo; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Yoshimasa Tokuchi; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Hajime Sakai; Shunsuke Ohnishi; Masaru Baba; Tetsuo Takehara; Naoya Sakamoto
    Scientific Reports, 12, 1, Springer Science and Business Media LLC, 2022年10月07日
    研究論文(学術雑誌), Abstract

    De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1β levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94–333.3). HCV-infected patients with the IL-1β gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1β levels; no HCV-infected patient with the IL-1β AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1β levels. Low IL-1β levels were not associated with HBV reactivation. IL-1β levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment.
  • Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination.
    Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    British journal of haematology, 2022年09月12日, [国際誌]
    英語
  • Impact of COVID-19 on international medical education and the future plans of medical students in Japan
    Houman Goudarzi; Masahiro Onozawa; Makoto Takahashi
    MedEdPublish, 12, 15, 15, F1000 Research Ltd, 2022年06月16日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌),

    Background: The aim of this study was to assess the impact of the coronavirus disease 2019 (COVID-19) pandemic on the current study methods and future plans of medical students compared to those in the pre-pandemic period.

    Methods: Second-grade medical students reported their academic experiences, study methods, and future career plans before (between 2016 and 2019) and during the pandemic (2020) using a questionnaire-based survey at Hokkaido University, Japan (n = 534).

    Results: From 2016 to 2019, we found an increasing trend for participation in short-term international exchange programs, taking the United States Medical Licensing Examination (USMLE), clinical training, and undertaking research abroad among the students. However, these percentages significantly declined (to 35.5%) during the COVID-19 pandemic in 2020 for all the assessed future plans, including short-term exchange programs (-27.9%), taking USMLE (-19.8%), clinical training (-24.5%), and undertaking research abroad (-13.2%) compared to 2019, wherein 67.9% of the students wished to have at least one of these four above-mentioned academic activities.

    Conclusions: The COVID-19 pandemic adversely and significantly influenced our medical students’ plans to go abroad for clinical and research training. Future studies are warranted to assess the long-term influence of this pandemic on the career planning of medical students.

  • Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
    Takayuki Ikezoe; Kiyoshi Ando; Masahiro Onozawa; Takahisa Yamane; Naoko Hosono; Yasuyoshi Morita; Toru Kiguchi; Hiromi Iwasaki; Toshihiro Miyamoto; Keisuke Matsubara; Saori Sugimoto; Yasushi Miyazaki; Masahiro Kizaki; Koichi Akashi
    Cancer science, 113, 12, 4258, 4266, 2022年06月11日, [国際誌]
    英語, 研究論文(学術雑誌), Therapeutic improvements are needed for patients with AML, particularly those who have relapsed or who have treatment-refractory (R/R) AML or newly diagnosed patients with poor prognostic factors. Alvocidib (DSP-2033), a potent cyclin-dependent kinase 9 inhibitor, has previously demonstrated promising clinical activity for the treatment of AML. In this multicenter, open-label, uncontrolled, 3+3 phase I study, we investigated the safety and tolerability of alvocidib administered in combination with either cytarabine and mitoxantrone (ACM) for R/R AML, or cytarabine/daunorubicin (A+7+3) for newly diagnosed AML. Alvocidib was administered to all patients as a 30-minute i.v. bolus (30 mg/m2 /d), followed by a continuous i.v. infusion over 4 hours on days 1-3 (60 mg/m2 /d). A total of 10 patients were enrolled: 6 received ACM (at 2 dose levels of cytarabine and mitoxantrone), and 4 received A+7+3. Alvocidib was tolerated and no dose-limiting toxicities were observed. All patients experienced adverse events, of which diarrhea was the most frequent (100%); hematologic events were also common. Alvocidib concentration peaked at the end of dosing (4.5 hours after start of administration), plasma accumulation after repeated dosing was minimal, and urinary excretion was negligible. The rate of complete remission/complete remission with incomplete hematologic recovery was 66.7% with the ACM regimen in R/R AML, including 4 complete remission (median duration 13.6 months) and 75% (3 complete remission) with the A+7+3 regimen. Further development of alvocidib in hematologic malignancies is warranted. The trial is registered with Clinicaltrials.gov: NCT03563560.
  • Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Alexander E Perl; Richard A Larson; Nikolai A Podoltsev; Stephen Strickland; Eunice S Wang; Ehab Atallah; Gary J Schiller; Giovanni Martinelli; Andreas Neubauer; Jorge Sierra; Pau Montesinos; Christian Récher; Sung-Soo Yoon; Naoko Hosono; Masahiro Onozawa; Shigeru Chiba; Hee-Je Kim; Nahla Hasabou; Qiaoyang Lu; Ramon Tiu; Mark J Levis
    Blood, 139, 23, 3366, 3375, 2022年06月09日, [国際誌]
    英語, 研究論文(学術雑誌), The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation-positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib in these patients with AML. At the time of this analysis, the median survival follow-up was 37.1 months, with deaths in 203 of 247 and 97 of 124 patients in the gilteritinib and SC arms, respectively; 16 gilteritinib-treated patients remained on treatment. The median overall survival for the gilteritinib and SC arms was 9.3 and 5.6 months, respectively (hazard ratio, 0.665; 95% confidence interval [CI], 0.518, 0.853; two-sided P = .0013); 2-year estimated survival rates were 20.6% (95% CI, 15.8, 26.0) and 14.2% (95% CI, 8.3, 21.6). The gilteritinib-arm 2-year cumulative incidence of relapse after composite complete remission was 75.7%, with few relapses occurring after 18 months. Overall, 49 of 247 patients in the gilteritinib arm and 14 of 124 patients in the SC arm were alive for ≥2 years. Twenty-six gilteritinib-treated patients remained alive for ≥2 years without relapse; 18 of these patients underwent transplantation (hematopoietic stem cell transplantation [HSCT]) and 16 restarted gilteritinib as post-HSCT maintenance therapy. The most common adverse events of interest during years 1 and 2 of gilteritinib therapy were increased liver transaminase levels; adverse event incidence decreased in year 2. Thus, continued and post-HSCT gilteritinib maintenance treatment sustained remission with a stable safety profile. These findings confirm that prolonged gilteritinib therapy is safe and is associated with superior survival vs SC. This trial was registered at www.clinicaltrials.gov as #NCT02421939.
  • Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Akio Mori; Masahiro Onozawa; Shihori Tsukamoto; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    British journal of haematology, 197, 6, 691, 696, 2022年06月, [国際誌]
    英語, 研究論文(学術雑誌), Data on the response to the COVID-19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titres were measured 3 months after the second mRNA-based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID-19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.
  • Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes.
    Shinpei Harada; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Hajime Senjo; Shogo Takahashi; Reiki Ogasawara; Minoru Kanaya; Akio Mori; Shuichi Ota; Takeshi Kondo; Takanori Teshima
    Annals of hematology, 101, 6, 1239, 1250, 2022年06月, [国際誌]
    英語, 研究論文(学術雑誌), Azacitidine (AZA) improves overall survival (OS) in patients with high-risk myelodysplastic syndromes (MDS). However, predictive factors for response to AZA remain largely unknown. To elucidate whether dynamic change in peripheral blood (PB) Wilms' Tumor 1 (WT1) mRNA levels could predict response to AZA, we retrospectively identified 75 treatment-naïve patients with high-risk MDS who received at least 3 cycles of AZA. We classified patients into 4 groups, low-increase (LI), low-stable (LS), high-decrease (HD), and high-stable (HS) based on the dynamic change in PB WT1 mRNA levels within 3 cycles of AZA. Cumulative incidence of overall response after 10 cycles of AZA was significantly higher in LS/HD than in HS/LI (75.5% vs 4.5%, P < 0.001). The median OS for LS/HD was 18.2 months (95% CI, 12.8-28.1 months), whereas it was 11.6 months for HS/LI (95% CI, 6.6-14.1 months; P < 0.001). Multivariate analysis demonstrated that poor-/very poor-IPSS-R cytogenetic risk and HS/LI were independently associated with poor OS (poor-/very poor-IPSS-R cytogenetic risk: HR, 2.26; 95% CI, 1.10-4.68, P = 0.03, HS/LI: HR, 2.32; 95% CI, 1.21-4.46, P = 0.01). Patients with HS/LI did not show any further response to continuous AZA, and they should be considered for alternative therapy from earlier cycles.
  • High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
    Hajime Senjo; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Daigo Hashimoto; Takeshi Kondo; Takanori Teshima
    Scientific reports, 12, 1, 8885, 8885, 2022年05月25日, [国際誌]
    英語, 研究論文(学術雑誌), Acute myeloid leukemia (AML) patients older than 65 years have a poor prognosis. Recently, CAR (C-reactive-protein/albumin ratio) has been actively reported as a prognostic index reflecting the nutritional and inflammatory status of elderly patients with solid tumors, but the usefulness of this index as a prognostic indicator in transplant-ineligible elderly AML patients has not been investigated. We studied genetic alterations and CARs in 188 newly diagnosed AML patients aged 65 years or older who were treated in a multicenter setting and had treated without HSCT. Both NCCN 2017 risk group, reflecting the genetic component of the tumor, and CAR, reflecting the inflammatory and nutritional status of the patient, successfully stratified the overall survival (OS) of the patients (2-year OS; CAR low vs high, 42.3% vs 17.8%, P < 0.001). Furthermore, in multivariate analysis, NCCN 2017 poor group and high CAR were extracted as independent poor prognostic factors predicting 2-year OS in the current study. We found, for the first time, that CAR at diagnosis predicted the prognosis of elderly patients with newly diagnosed AML treated without HSCT.
  • Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
    Akio Mori; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Toru Miyajima; Emi Yokoyama; Reiki Ogasawara; Koh Izumiyama; Makoto Saito; Shinichi Fujisawa; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Hiroshi Iwasaki; Hajime Kobayashi; Yoshihito Haseyama; Mitsutoshi Kurosawa; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
    International journal of hematology, 115, 2, 188, 197, 2022年02月, [国内誌]
    英語, 研究論文(学術雑誌), In this real-world clinical study, in which we determined eligibility for allogenic hematopoietic stem cell transplantation by prognostic factors and minimal residual disease status, we retrospectively evaluated cytogenetic, genetic, and clinical features in 96 patients with core-binding factor acute myeloid leukemia (CBF-AML) including 62 patients with RUNX1/RUNX1T1 and 34 patients with CBFβ/MYH11. Multivariate analyses for 5-year overall survival (OS) in CBF-AML patients revealed that age of 50 years or older (HR: 3.46, 95% CI 1.47-8.11, P = 0.004) and receiving 2 or more induction cycles (HR: 3.55, 95% CI 1.57-8.05, P = 0.002) were independently associated with worse OS and that loss of sex chromosome (LOS) was independently associated with better OS (HR: 0.09, 95% CI 0.01-0.71, P = 0.022). At the time of complete remission, all 21 karyotyped patients with LOS had a normal karyotype. Furthermore, in all 9 patients with LOS who had a mosaic of metaphase cells with and without t(8;21) or inv(16), the metaphase cells without t(8;21)/inv(16) showed a normal karyotype. These results proved that LOS was not age-related and physiological, but rather a neoplastic chromosomal abnormality.
  • [Bing-Neel syndrome successfully treated with tirabrutinib].
    Keito Yokoyama; Hiroyuki Ohigashi; Toru Miyajima; Naoki Miyashita; Satomi Okada; Yuta Hasegawa; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Takanori Teshima
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 63, 8, 870, 875, 2022年, [国内誌]
    日本語, 研究論文(学術雑誌), Bing-Neel syndrome (BNS) is a rare disease manifestation of Waldenström's macroglobulinemia characterized by abnormal lymphoplasmacytoid cells infiltration of the central nervous system. In September 2019, a 46-year-old man presented to a previous hospital with hand tremors, nausea, and dysuria. Demyelination of cerebral white matter and the spinal cord was discovered using MRI. Steroid pulse therapy was used to treat inflammatory demyelinating disease, and it provided temporary relief, but the symptoms returned when the steroids were stopped. He was referred to our hospital in June 2020, for further evaluation with the possibility of hematological malignancy. BNS was diagnosed based on the presence of abnormal lymphoplasmacytoid cells in the bone marrow and cerebrospinal fluid (CSF), as well as the presence of the MYD88L265P mutation in the CSF specimen. In July 2020, BR (bendamustine, rituximab) therapy was administered, but it was ineffective. Oral administration of tirabrutinib, which was recently approved for WM, began in August 2020. He has achieved long-term remission and steroid withdrawal, with no notable side effects. This is the second report of successful treatment of BNS with tirabrutinib. More research is needed to confirm tirabrutinib's efficacy in the treatment of BNS.
  • Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib.
    Takeshi Kondo; Masahiro Onozawa; Shinichi Fujisawa; Shinpei Harada; Reiki Ogasawara; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Akio Mori; Takanori Teshima
    Hematology (Amsterdam, Netherlands), 26, 1, 256, 260, 2021年12月, [国際誌]
    英語, 研究論文(学術雑誌), Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myelogenous leukemia (AML) and the mutation is associated with poor prognosis of patients. Two distinct types of activating mutations have been identified in AML samples. One is internal tandem duplications in the juxtamembrane domain (FLT3-ITD) and the other is point mutations in the tyrosine kinase domain (FLT3-TKD). Gilteritinib is a FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD. It was reported that differentiation of leukemic blasts accompanied by differentiation syndrome occurs in some patients treated with gilteritinib. However, information about the precise clinical course is limited, and appropriate management of differentiation syndrome has not been established. We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.
  • Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL.
    Liat Goldberg; Vijay Negi; Yang Jo Chung; Masahiro Onozawa; Yuelin J Zhu; Robert L Walker; Rachel Pierce; Daxesh P Patel; Kristopher W Krausz; Frank J Gonzalez; Margaret A Goodell; Benjamin A T Rodriguez; Paul S Meltzer; Peter D Aplan
    Cancer research, 81, 19, 5033, 5046, 2021年10月01日, [国際誌]
    英語, 研究論文(学術雑誌), Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are frequently observed in a wide variety of hematologic malignancies, including myeloid and T-cell leukemias. In this study, we generated Idh2R140Q transgenic mice to examine the role of the Idh2R140Q mutation in leukemia. No leukemia developed in Idh2R140Q transgenic mice, suggesting a need for additional genetic events for leukemia development. Because myeloid cells from NUP98-HOXD13 fusion (NHD13) transgenic mice frequently acquire somatic Idh mutations when they transform to acute myeloid leukemia, we generated Idh2R140Q/NHD13 double transgenic mice. Idh2R140Q/NHD13 transgenic mice developed an immature T-cell leukemia with an immunophenotype similar to double-negative 1 (DN1) or DN2 thymocytes. Idh2R140Q/NHD13 leukemic cells were enriched for an early thymic precursor transcriptional signature, and the gene expression profile for Idh2R140Q/NHD13 DN1/DN2 T-ALL closely matched that of human early/immature T-cell precursor (EITP) acute lymphoblastic leukemia (ALL). Moreover, recurrent mutations found in patients with EITP ALL, including KRAS, PTPN11, JAK3, SH2B3, and EZH2 were also found in Idh2R140Q/NHD13 DN1/DN2 T-ALL. In vitro treatment of Idh2R140Q/NHD13 thymocytes with enasidenib, a selective inhibitor of mutant IDH2, led to a marked decrease in leukemic cell proliferation. These findings demonstrate that Idh2R140Q/NHD13 mice can serve as a useful in vivo model for the study of early/immature thymocyte precursor acute lymphoblastic leukemia development and therapy. SIGNIFICANCE: T-cell leukemia induced in Idh2R140Q/NUP98-HOXD13 mice is immunophenotypically, transcriptionally, and genetically similar to human EITP ALL, providing a model for studying disease development and treatment.
  • Aleukemic Extramedullary Blast Crisis as an initial presentation of Chronic Myeloid Leukemia with E1A3 BCR-ABL1 Fusion Transcript.
    Naoki Miyashita; Masahiro Onozawa; Keito Suto; Shinichi Fujisawa; Nanase Okazaki; Daisuke Hidaka; Hiroyuki Ohigashi; Atsushi Yasumoto; Junichi Sugita; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
    Internal medicine (Tokyo, Japan), 61, 7, 1049, 1054, 2021年09月11日, [国内誌]
    英語, 研究論文(学術雑誌), Right neck swelling and pain occurred in a 49-year-old man. A Blood count showed a slight increase in platelet count without leukemoid reaction. After a biopsy of the cervical mass and bone marrow aspiration, a diagnosis of extramedullary blast crisis (EBC) of chronic myeloid leukemia (CML) was made. FISH analysis showed a BCR-ABL1 fusion signal, but results of RT-PCR for major and minor BCR-ABL1 transcripts were negative. We identified a rare e1a3 BCR-ABL1 fusion transcript. Administration of dasatinib resulted in disappearance of the extramedullary tumor. This is the first reported case of CML-EBC with e1a3 transcript. An aleukemic extramedullary tumor can be the initial presentation of CML.
  • AMLとして発症したmyeloid/lymphoid neoplasms with t(8;9)(p22;p24);PCM1-JAK2(Acute myeloid leukemia with t(8;9)(p22;p24); PCM1-JAK2)
    盛 暁生; 小野澤 真弘; 宮島 徹; 塚本 しほり; 石尾 崇; 横山 絵美; 小笠原 励起; 泉山 康; 斎藤 誠; 小田 義崇; 森岡 正信; 近藤 健
    日本血液学会学術集会, 83回, PS, 5, (一社)日本血液学会, 2021年09月
    英語
  • Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.
    Emilia J Kozyra; Gudrun Gohring; Dennis D Hickstein; Katherine R Calvo; Courtney D DiNardo; Michael Dworzak; Valerie de Haas; Jan Stary; Henrik Hasle; Akiko Shimamura; Mark D Fleming; Hiroto Inaba; Sara Lewis; Amy P Hsu; Steven M Holland; Danielle E Arnold; Cristina Mecucci; Sioban B Keel; Alison A Bertuch; Kiran Tawana; Shlomit Barzilai-Birenboim; Shinsuke Hirabayashi; Masahiro Onozawa; Shaohua Lei; Helena Alaiz; Hajnalka Andrikovics; David Betts; H Berna Beverloo; Jochen Buechner; Martin Čermák; Jose Cervera; Olga Haus; Kirsi Jahnukainen; Kalliopi Manola; Karin Nebral; Francesco Pasquali; Joelle Tchinda; Dominik Turkiewicz; Nadine Van Roy; Zuzana Zemanova; Victor B Pastor; Brigitte Strahm; Peter Nöllke; Charlotte M Niemeyer; Brigitte Schlegelberger; Ayami Yoshimi; Marcin W Wlodarski
    Blood, 138, 23, 2441, 2445, 2021年09月01日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
    Naoko Hosono; Hisayuki Yokoyama; Nobuyuki Aotsuka; Kiyoshi Ando; Hiroatsu Iida; Takayuki Ishikawa; Kensuke Usuki; Masahiro Onozawa; Masahiro Kizaki; Kohmei Kubo; Junya Kuroda; Yukio Kobayashi; Takayuki Shimizu; Shigeru Chiba; Miho Nara; Tomoko Hata; Michihiro Hidaka; Shin-Ichiro Fujiwara; Yoshinobu Maeda; Yasuyoshi Morita; Mikiko Kusano; Qiaoyang Lu; Shuichi Miyawaki; Erhan Berrak; Nahla Hasabou; Tomoki Naoe
    International journal of clinical oncology, 26, 11, 2131, 2141, 2021年08月07日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+ R/R AML based on the phase 3 ADMIRAL trial, which demonstrated the superiority of gilteritinib over salvage chemotherapy (SC) with respect to overall survival (OS; median OS, 9.3 vs 5.6 months, respectively; hazard ratio, 0.64 [95% confidence interval 0.49, 0.83]; P < 0.001). METHODS: We evaluated the Japanese subgroup (n = 48) of the ADMIRAL trial, which included 33 patients randomized to 120-mg/day gilteritinib and 15 randomized to SC. RESULTS: Median OS was 14.3 months in the gilteritinib arm and 9.6 months in the SC arm. The complete remission/complete remission with partial hematologic recovery rate was higher in the gilteritinib arm (48.5%) than in the SC arm (13.3%). After adjustment for drug exposure, fewer adverse events (AEs) occurred in the gilteritinib arm than in the SC arm. Common grade ≥ 3 AEs related to gilteritinib were febrile neutropenia (36%), decreased platelet count (27%), and anemia (24%). CONCLUSION: Findings in Japanese patients are consistent with those of the overall ADMIRAL study population.
  • ZBTB16-RARα変異陽性急性前骨髄性白血病(APL)
    塚本 しほり; 江端 浩; 高橋 正二郎; 森 祐斗; 吉田 匠汰; 笠原 耕平; 岩崎 純子; 岡田 耕平; 小野澤 真弘; 皆内 康一郎; 小笠原 正浩; 小林 直樹; 今村 雅寛; 太田 秀一
    臨床血液, 62, 7, 847, 847, (一社)日本血液学会-東京事務局, 2021年07月
    日本語
  • XIAP欠損症に対して非血縁者間骨髄移植を施行して移植後赤芽球癆を認めた1例
    千葉 雅尋; 杉田 純一; 宮下 直樹; 須藤 啓斗; 日高 大輔; 大東 寛幸; 安本 篤史; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳
    臨床血液, 62, 7, 848, 849, (一社)日本血液学会-東京事務局, 2021年07月
    日本語
  • 髄外腫瘤で発症したe1a3 BCR-ABL陽性慢性骨髄性白血病
    宮下 直樹; 小野澤 真弘; 須藤 啓斗; 日高 大輔; 大東 寛幸; 安本 篤史; 杉田 純一; 橋本 大吾; 豊嶋 崇徳
    臨床血液, 62, 7, 849, 849, (一社)日本血液学会-東京事務局, 2021年07月
    日本語
  • High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
    Souichi Shiratori; Hiroyuki Ohigashi; Takahide Ara; Atsushi Yasumoto; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Annals of hematology, 100, 5, 1321, 1328, 2021年05月, [国際誌]
    英語, 研究論文(学術雑誌), Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 109/L vs 0.06 × 109/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD.
  • Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.
    Satoru Kase; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Takako Ito; Keitaro Hase; Kayo Suzuki; Masahiro Onozawa; Nobuyoshi Kitaichi; Susumu Ishida
    Cancer diagnosis & prognosis, 1, 2, 69, 75, 2021年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL). PATIENTS AND METHODS: Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement. RESULTS: Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation. CONCLUSION: Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period.
  • [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
    Shinpei Harada; Kohei Okada; Shota Yokoyama; Daisuke Hidaka; Eiko Hayase; Masahiro Onozawa; Hideki Goto; Daigo Hashimoto; Kaoru Kahata; Tomoyuki Endo; Takanori Teshima
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 62, 11, 1609, 1614, 2021年, [国内誌]
    日本語, 研究論文(学術雑誌), A 25-year-old male with a medical history of stress polycythemia was admitted to a previous hospital for leukocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed left-shifted myeloid hyperplasia without increased blasts and normal male karyotype. No mutations of JAK2, V617F, and colony-stimulating factor 3 receptor gene (CSF3R) were detected. Fluorescence in-situ hybridization for BCR-ABL1 and FIP1L1-PDGFRA were negative. Based on these findings, a diagnosis of an unclassifiable myeloproliferative neoplasm was made, and he was started on hydroxyurea treatment. He was referred to our hospital in April 2016 for transfusion dependence. Bone marrow examination performed at our hospital revealed granulocytic dysplasia and CSF3R T618I was detected. After induction therapy, CSF3R T618I became undetectable, and he went on to undergo allogeneic stem cell transplantation in October 2016. He has been in remission for >4 years posttransplantation. CSF3R T618I is one of the genes responsible for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, suggesting its involvement in the pathogenesis of this case.
  • 急性前骨髄球性白血病に対する同種造血幹細胞移植27年後に発症したドナー細胞由来未分化大細胞リンパ腫の1例
    菊池 遼; 小野澤 真弘; 今本 鉄平; 高橋 秀一郎; 杉田 純一; 橋本 大吾; 橋野 聡; 松野 吉宏; 豊嶋 崇徳
    日本内科学会雑誌, 110, 1, 92, 98, (一社)日本内科学会, 2021年01月
    日本語, 54歳男性。右鼠径リンパ節腫脹を主訴とした。27歳時に急性前骨髄球性白血病に対しHLA適合の兄から骨髄移植を受けていた。53歳時に右大腿外側部にケロイド様皮疹が出現し、皮膚生検の診断はanaplastic lymphoma kinase(ALK)陰性の未分化大細胞リンパ腫(ALCL)であった。電子線治療で皮膚病変は消失したが、7ヵ月後にFDG-PETで全身のリンパ節病変(鎖骨上窩、傍大動脈、右鼠径部)を認めた。再発病変を疑い、右鼠径リンパ節を生検したところ、右大腿皮膚生検同様の組織所見を認め、ALK陰性ALCLと診断した。末梢血をドナー細胞、頬粘膜をレシピエント細胞としてキメリズム解析を行い、ドナー由来のALCLと診断した。ALCLに対しCHOP療法(cyclophosphamide、doxorubicin、vincristine、prednisolone)を行ったが、病変の増大を認め、brentuximab vedotin(BV)単剤による治療に変更した。経過は良好で、現在まで完全奏効を維持している。
  • A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia.
    Hajime Senjo; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Daigo Hashimoto; Takeshi Kondo; Takanori Teshima
    Scientific reports, 10, 1, 19400, 19400, 2020年11月10日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process.
    Daisuke Hidaka; Masahiro Onozawa; Naohiro Miyashita; Shota Yokoyama; Masao Nakagawa; Daigo Hashimoto; Takanori Teshima
    Leukemia & lymphoma, 61, 11, 2722, 2732, 2020年11月, [国際誌]
    英語, 研究論文(学術雑誌), Imetelstat is a specific and competitive inhibitor of telomerase enzymatic activity. We demonstrated that imetelstat could interfere with the DNA repair process and enhance the effect of DNA damaging agents using hematological tumor cell lines. Short-term administration of imetelstat enhanced growth suppression by anticancer agents and radiation. It also upregulated γH2AX expression induced by irradiation. Immunofluorescence staining showed that both human telomerase reverse transcriptase (hTERT) and γH2AX were upregulated and co-localized in the nucleus of peripheral blood mononuclear cells after irradiation, suggesting that hTERT was involved in the DNA-DSB repair process. Imetelstat enhanced growth inhibitory effect of cytotoxic agents in short-term culture without shortening of telomeres, indicating that this effect was attributed by telomere length independent mechanism. Our results suggest that the combination of short-term treatment with imetelstat and cytotoxic agent is a promising strategy to treat a wide variety of hematopoietic malignancies.
  • 臍帯血移植後のドナー由来細胞にモノソミー7を認めたAMLの一症例
    佐藤 かおり; 小栗 聡; 市川 絢子; 藤澤 真一; 西田 睦; 杉田 純一; 小野澤 真弘; 豊嶋 崇徳
    日本医学検査学会抄録集, 69回, 399, 399, (一社)日本臨床衛生検査技師会, 2020年09月
    日本語
  • Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.
    Hideki Goto; Daisuke Hidaka; Satoshi Yamamoto; Koji Hayasaka; Rie Michimata; Ikuko Kagawa; Kana Sunagoya; Hiroaki Iijima; Eiko Hayase; Souichi Shiratori; Kohei Okada; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Chikara Shimizu; Takanori Teshima
    Journal of clinical apheresis, 35, 5, 413, 419, 2020年09月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma. STUDY DESIGN AND METHODS: Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis. RESULTS: In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation. CONCLUSION: Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells.
  • Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8.
    Takahide Ara; Daigo Hashimoto; Eiko Hayase; Clara Noizat; Ryo Kikuchi; Yuta Hasegawa; Kana Matsuda; Shoko Ono; Yoshihiro Matsuno; Ko Ebata; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Emi Yokoyama; Keitaro Matsuo; Junichi Sugita; Masahiro Onozawa; Ryu Okumura; Kiyoshi Takeda; Takanori Teshima
    Science translational medicine, 12, 550, 2020年07月01日, [国際誌]
    英語, 研究論文(学術雑誌), Graft-versus-host disease (GVHD) and infection are major obstacles to successful allogeneic hematopoietic stem cell transplantation (HSCT). Intestinal goblet cells form the mucus layers, which spatially segregate gut microbiota from host tissues. Although it is well known that goblet cell loss is one of the histologic features of GVHD, effects of their loss in pathophysiology of GVHD remain to be elucidated. In mouse models of allogeneic HSCT, goblet cells in the colon were significantly reduced, resulting in disruption of the inner mucus layer of the colon and increased bacterial translocation into colonic mucosa. Pretransplant administration of interleukin-25 (IL-25), a growth factor for goblet cells, protected goblet cells against GVHD, prevented bacterial translocation, reduced plasma concentrations of interferon-γ (IFN-γ) and IL-6, and ameliorated GVHD. The protective role of IL-25 was dependent on Lypd8, an antimicrobial molecule produced by enterocytes in the colon that suppresses motility of flagellated bacteria. In clinical colon biopsies, low numbers of goblet cells were significantly associated with severe intestinal GVHD, increased transplant-related mortality, and poor survival after HSCT. Goblet cell loss is associated with poor transplant outcome, and administration of IL-25 represents an adjunct therapeutic strategy for GVHD by protecting goblet cells.
  • Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: case report based on multimodal imaging.
    Kanae Fukutsu; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Satoru Kase; Kayo Suzuki; Hiroshi Shimizu; Yukiko Shibata; Fumihiko Yamawaki; Masahiro Onozawa; Susumu Ishida
    BMC ophthalmology, 20, 1, 94, 94, 2020年03月10日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Hematologic malignancies occasionally cause serous retinal detachment (SRD); however, its pathogenesis remains unclear. Here we present the imaging characteristics of metastatic choroidal lymphoma masquerading as Vogt-Koyanagi-Harada (VKH) disease. CASE PRESENTATION: A 45-year-old Japanese woman was referred to our clinic because of bilateral SRD with blurred vision. Fluorescein angiography revealed multiple pinpoint leakage followed by pooling OU. Enhanced depth imaging optical coherence tomography showed marked choroidal thickening OU. Laser speckle flowgraphy detected choroidal circulation impairment OU. Although these results totally agreed with the inflammatory manifestations of acute VKH disease, indocyanine green angiography demonstrated various sizes of sharply marginated hypofluorescent lesions that seemed atypical for the finding of VKH disease, i.e., vaguely marginated hypofluorescent small dots. Cerebrospinal fluid pleocytosis was not detected. Blood tests revealed leukocytosis together with elevation of lactate dehydrogenase and soluble interleukin-2 receptor levels. Corticosteroid pulse therapy did not improve any ocular findings. Bone marrow biopsy was then performed, leading to a definite diagnosis of diffuse large B-cell lymphoma. After starting systemic chemotherapy, both SRD and choroidal thickening resolved rapidly with visual recovery. However, choroidal hypoperfusion persisted, which contrasted distinctly with the inflammatory pattern of VKH disease, i.e., the restoration of choroidal blood flow in parallel with normalization of choroidal thickness. CONCLUSIONS: Our detailed multimodal observations highlighted the differential imaging features of choroidal lymphoma despite close resemblance to VKH disease especially at the initial stage. Impaired circulation in the thickened choroid marked the pseudo-inflammatory pathogenesis of SRD due to choroidal involvement with neoplastic, but not inflammatory cells.
  • 異型上皮の過剰増殖を伴う皮膚未分化大細胞リンパ腫
    清水 亜衣; 大塚 拓也; 高桑 恵美; 岡田 宏美; 柳 輝希; 小野澤 真弘; 畑中 豊; 三橋 智子; 阿南 隆; 松野 吉宏
    日本病理学会会誌, 109, 1, 389, 389, (一社)日本病理学会, 2020年03月
    日本語
  • Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
    Souichi Shiratori; Hiroyuki Ohigashi; Shuichiro Takahashi; Takahide Ara; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Annals of hematology, 99, 3, 591, 598, 2020年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM.
  • Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
    Reiki Ogasawara; Daigo Hashimoto; Junichi Sugita; Fumihiko Yamawaki; Tomoaki Naka; Tomoko Mitsuhashi; Shuichiro Takahashi; Naohiro Miyashita; Kohei Okada; Masahiro Onozawa; Yoshihiro Matsuno; Takanori Teshima
    International journal of hematology, 111, 3, 475, 479, 2020年03月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Nivolumab is effective in the treatment of classical Hodgkin lymphoma that relapsed after allogeneic hematopoietic stem cell transplantation (SCT) with the risk of graft-versus-host disease; however, the optimal time and dose of nivolumab administration remain to be investigated. Nivolumab binding to PD-1 masks flowcytometric detection of PD-1 by the anti-PD-1 monoclonal antibody EH12.1. Using this method, we monitored nivolumab binding on T cells after nivolumab treatment in a patient with classical Hodgkin lymphoma relapsed after allogeneic SCT. Nivolumab was effective while prolonged nivolumab binding was evident, but restoration of PD-1 staining predicted tumor relapse. Flowcytometric monitoring of nivolumab binding on T cells could be a promising biomarker for predicting tumor relapse and determining the timing of nivolumab administration.
  • A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation.
    Koji Nishikawa; Kiminori Kimura; Yoshinobu Kanda; Masaya Sugiyama; Kazuhiko Kakihana; Noriko Doki; Kazuteru Ohashi; Sung Kwan Bae; Kazuhiro Takahashi; Yuko Ishihara; Ishikazu Mizuno; Yasushi Onishi; Masahiro Onozawa; Makoto Onizuka; Masahide Yamamoto; Tetsuya Ishikawa; Kazuaki Inoue; Shigeru Kusumoto; Satoshi Hashino; Hidetsugu Saito; Tatsuya Kanto; Hisashi Sakamaki; Masashi Mizokami
    Bone marrow transplantation, 55, 7, 1388, 1398, 2020年02月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis B virus (HBV) reactivation reportedly occurs frequently after hematopoietic stem cell transplantation (HSCT) in resolved HBV-infected patients. Here, 50 patients with resolved HBV infections and scheduled to undergo HSCT were enrolled; all subjects were vaccinated with three doses of hepatitis B vaccine 12 months after HSCT and the incidence of HBV reactivation was monitored. The patients' characteristics were: median age, 61 (34-72) years; male/female, 27/19; allogeneic/autologous, 40/6; bone marrow/peripheral blood stem cells/cord blood, 26/16/4. Of the 46 patients who underwent HSCT, 19 were excluded and did not make it to vaccination due to relapse of underlying disease, HBV reactivation within 12 months of HSCT, or transfer of patients. The remaining 27 were vaccinated 12 months after HSCT and monitored for 2 years. Six showed HBV reactivation, with a 2-year cumulative reactivation incidence of 22.2%; the same incidence was 27.3% only in allogeneic HSCT patients. Factors associated with HBV reactivation included the discontinuation of immunosuppressants (P = 0.0379) and baseline titers of antibody against hepatitis B surface antigen (P = 0.004). HBV reactivation with vaccination following HSCT could occur despite maintenance of serum anti-HBs at more than protective levels.
  • Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody
    Maria Regina Pelobello de Leon; Shuichiro Takahashi; Masahiro Onozawa; Makoto Ito; Manabu Nakano; Hajime Senjo; Masahiro Chiba; Hiroyuki Ohigashi; Emi Yokoyama; Junichi Sugita; Daigo Hashimoto; Takanori Teshima
    BLOOD CELL THERAPY / The official journal of APBMT, 3, 3, 74, 77, Asia-Pacific Blood and Marrow Transplantation Group, 2020年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for various kinds of hematological malignancies and disorders. Recently, HLA-haploidentical stem cell transplantation with post-transplantation cyclophosphamide (PTCy-haplo HSCT) has been widely performed due to its safety and favorable immune recovery. However, graft rejection remains an obstacle to PTCy-haplo HSCT. Donor specific antibody (DSA) is considered to be a major factor of graft rejection of haplo HSCT. We herein present a case of graft rejection after PTCy haplo-HSCT due to DSA induced by pretransplant platelet transfusion after donor selection. The patient was dependent on platelet transfusion and had not received cytotoxic chemotherapy because he was diagnosed as myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable. We retrospectively confirmed the level of DSA just before the first transplantation and found that it was dramatically elevated, which was enough to cause graft rejection. We successfully performed cord blood transplantation of the HLA that was not the target of DSA, as salvage transplantation without any desensitization. This case illustrates that we have to confirm the presence of DSA immediately before the haplo-HSCT, particularly in high risk patients who are dependent on platelet transfusion and have no cytotoxic chemotherapy before HSCT.
  • Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
    Jun Sakakibara-Konishi; Mineyoshi Sato; Michiko Takimoto Sato; Kohei Kasahara; Masahiro Onozawa; Hidenori Mizugaki; Eiki Kikuchi; Hajime Asahina; Naofumi Shinagawa; Satoshi Konno
    Respiratory medicine case reports, 31, 101170, 101170, 2020年, [国際誌]
    英語, Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related to better outcome of nivolumab. Frequency of hematological irAE is low and there are few reports about hematological irAE and association between irAE and outcome of nivolumab in patients with MPM. We present a case of recurrent MPM who responded to nivolumab treatment and experienced nivolumab-induced immune thrombocytopenia (ITP). Although high dose dexamethasone was administered and platelet count increased transiently, re-administration of dexamethasone was required to maintain normal count of platelet. The careful and intensive management of ITP treatment is necessary in cases who show no response or relapse to initial glucocorticoids treatment. This is the first report about nivolumab-induced ITP and association with response to nivolumab in MPM.
  • Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets.
    Naohiro Miyashita; Masahiro Onozawa; Shota Yokoyama; Daisuke Hidaka; Koji Hayasaka; Shinji Kunishima; Takanori Teshima
    HemaSphere, 3, 4, e268, 2019年08月, [国際誌]
    英語, 研究論文(学術雑誌), We retrospectively evaluated 48 essential thrombocythemia (ET) patients who were treated in our institute (male/female, 14/34, median age, 61.5 years). In 14 patients treated with anagrelide (ANA), the degree of platelet count reduction (median, -56.6%) was strongly correlated with increase of mean platelet volume (MPV) (median, +11.7%) (R = 0.777). This correlation was not observed in ET patients treated with hydroxycarbamide alone (R = 0.245). The change in size of platelets strongly suggested that ANA affected the final process of platelet production. Thus, we hypothesized that ANA modifies the process by which platelets are released from proplatelets. To verify the association in an in vitro setting, we compared MEG-01 cells treated with PMA ± ANA. The number of platelet-like particles (PLPs) was decreased (P < 0.05) and the size of PLPs estimated by using flow cytometry was significantly increased when MEG-01 cells were treated with PMA + ANA (P < 0.05 vs PMA alone), recapitulating the clinical findings. The cytoplasmic protrusions extending from MEG-01 cells were shorter and thicker and the number of proplatelets was decreased when MEG-01 cells were treated with PMA + ANA (P < 0.01 vs PMA alone). Western blotting analysis showed that ANA treatment resulted in increased phosphorylation of MLC2 and reduced phosphorylation of focal adhesion kinase (FAK). The morphological change of proplatelets were reversed by blebbistatin, a specific inhibitor of myosin II. These findings indicated that ANA modulates the FAK-RhoA-ROCK-MLC2-myosine IIA pathway and suppresses proplatelet maturation, leading to a decrease in platelet count and increase in MPV.
  • Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Keisuke Kataoka; Hiroaki Miyoshi; Seiji Sakata; Akito Dobashi; Lucile Couronné; Yasunori Kogure; Yasuharu Sato; Kenji Nishida; Yuka Gion; Yuichi Shiraishi; Hiroko Tanaka; Kenichi Chiba; Yosaku Watatani; Nobuyuki Kakiuchi; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masashi Sanada; Masahiro Onozawa; Takanori Teshima; Yumiko Yoshiki; Tadao Ishida; Kenshi Suzuki; Kazuyuki Shimada; Akihiro Tomita; Motohiro Kato; Yasunori Ota; Koji Izutsu; Ayako Demachi-Okamura; Yoshiki Akatsuka; Satoru Miyano; Tadashi Yoshino; Philippe Gaulard; Olivier Hermine; Kengo Takeuchi; Koichi Ohshima; Seishi Ogawa
    Leukemia, 33, 7, 1687, 1699, 2019年07月, [国際誌]
    英語, 研究論文(学術雑誌), Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.
  • The myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease
    豊嶋 崇徳
    Haematologica, 105, 1, 226, 234, 2019年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Myeloid differentiation factor 88 (MyD88) signaling has a crucial role in activation of both innate and adoptive immunity. MyD88 transduces signals via Toll-like receptor and interleukin-1 receptor superfamily to the NFκB pathway and inflammasome by forming a molecular complex with interleukin-1 receptor-associated kinase 4. The MyD88/interleukin-1 receptor-associated kinase 4 pathway plays an important role, not only in innate immunity, but also T-cell immunity; however, its role in donor T cells on the pathophysiology of graft-versus-host disease (GvHD) remains to be elucidated. We addressed this issue by using MyD88-deficient T cells in a mouse model of allogeneic hematopoietic stem cell transplantation (allo-SCT). While MyD88-deficient and wild-type T cells proliferated equivalently after transplantation, MyD88-deficient T cells demonstrated impaired survival and differentiation toward Th1, Tc1, and Th17, and induced less severe GvHD compared to wild-type T cells. Administration of interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 significantly ameliorated GvHD after allo-SCT. These results thus demonstrate that donor T-cell MyD88/interleukin-1 receptor-associated kinase 4 pathway is a novel therapeutic target against GvHD after allo-SCT.
  • Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
    豊嶋 崇徳
    Nat Med, 25, 4, 603, 611, 2019年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-γ or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies.
  • Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD
    豊嶋 崇徳
    Blood Adv, 3, 7, 1003, 1010, 2019年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Chronic graft-versus-host disease (GVHD) profoundly affects the quality of life of long-term survivors of allogeneic hematopoietic stem cell transplantation (SCT). The eyes are frequently involved, and dry eye syndrome is the most common manifestation of ocular chronic GVHD. We explored the role of heat shock protein 47 (HSP47) in ocular GVHD and developed a novel antifibrotic topical therapy using vitamin A-coupled liposomes containing HSP47 small interfering RNA (siRNA) against HSP47 (VA-lip HSP47). In a mouse model of chronic GVHD, infiltration of HSP47+ fibroblasts and massive fibrosis surrounding the lacrimal ducts were observed after allogeneic SCT, leading to impaired tear secretion. After ocular instillation, VA-lip HSP47 was distributed to the lacrimal glands, knocked down HSP47 expression in fibroblasts, reduced collagen deposition, and restored tear secretion after allogeneic SCT. Ocular instillation of VA-lip HSP47 also ameliorated established lacrimal gland fibrosis and dry eye syndrome. VA-lip HSP47 eye drops are a promising prophylactic and therapeutic option against dry eye syndrome in chronic GVHD.
  • Quantitative detection of IKZF1 deletion by digital PCR in patients with acute lymphoblastic leukemia
    豊嶋 崇徳
    Int J Lab Hematol, 41, 2, e38, e40, Wiley, 2019年04月, [査読有り]
    研究論文(学術雑誌)
  • Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
    Maddalena Noviello; Francesco Manfredi; Eliana Ruggiero; Tommaso Perini; Giacomo Oliveira; Filippo Cortesi; Pantaleo De Simone; Cristina Toffalori; Valentina Gambacorta; Raffaella Greco; Jacopo Peccatori; Monica Casucci; Giulia Casorati; Paolo Dellabona; Masahiro Onozawa; Takanori Teshima; Marieke Griffioen; Constantijn J M Halkes; J H F Falkenburg; Friedrich Stölzel; Heidi Altmann; Martin Bornhäuser; Miguel Waterhouse; Robert Zeiser; Jürgen Finke; Nicoletta Cieri; Attilio Bondanza; Luca Vago; Fabio Ciceri; Chiara Bonini
    Nature communications, 10, 1, 1065, 1065, 2019年03月25日, [国際誌]
    英語, 研究論文(学術雑誌), The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating the bone marrow (BM) of 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) after HSCT. A higher proportion of early-differentiated Memory Stem (TSCM) and Central Memory BM-T cells express multiple IR in relapsing patients than in CR patients. Exhausted BM-T cells at relapse display a restricted TCR repertoire, impaired effector functions and leukemia-reactive specificities. In 57 patients, early detection of severely exhausted (PD-1+Eomes+T-bet-) BM-TSCM predicts relapse. Accordingly, leukemia-specific T cells in patients prone to relapse display exhaustion markers, absent in patients maintaining long-term CR. These results highlight a wide, though reversible, immunological dysfunction in the BM of AML patients relapsing after HSCT and suggest new therapeutic opportunities for the disease.
  • Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma.
    Kase S; Namba K; Kanno-Okada H; Onozawa M; Hidaka D; Iwata D; Mizuuchi K; Fukuhara T; Fukuhara J; Kitaichi N; Matsuno Y; Ishida S
    Ocular immunology and inflammation, 1, 9, 2018年10月, [査読有り]
  • The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
    Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Clinical transplantation, 32, 9, e13361, 2018年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings.
  • 成人急性リンパ性白血病におけるIKZF1欠失およびCRLF2発現の解析(Analysis of IKZF1 deletion and CRLF2 expression in adult patients with acute lymphoblastic leukemia)
    橋口 淳一; 小野澤 真弘; 藤澤 真一; 高橋 秀一郎; 宮下 直洋; 早瀬 英子; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 橋本 大吾; 加畑 馨; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 岩崎 博; 近藤 健; 豊嶋 崇徳
    臨床血液, 59, 9, 1648, 1648, (一社)日本血液学会-東京事務局, 2018年09月
    英語
  • Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia
    Junichi Hashiguchi; Masahiro Onozawa; Satoshi Oguri; Shinichi Fujisawa; Masahisa Tsuji; Kohei Okada; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Takeshi Kondo; Chikara Shimizu; Takanori Teshima
    Journal of Molecular Diagnostics, 20, 4, 446, 454, Elsevier B.V., 2018年07月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intestinal Lymphatic Endothelial Cells Produce R-Spondin3.
    Ogasawara R; Hashimoto D; Kimura S; Hayase E; Ara T; Takahashi S; Ohigashi H; Yoshioka K; Tateno T; Yokoyama E; Ebata K; Kondo T; Sugita J; Onozawa M; Iwanaga T; Teshima T
    Scientific reports, 8, 1, 10719, 10719, 2018年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The R-Spondin (R-Spo) family regulates WNT signaling and stimulates the proliferation and differentiation of intestinal stem cells (ISCs). R-Spo plays a critical role in maintaining intestinal homeostasis, but endogenous producers of R-Spo in the intestine remain to be investigated. We found that R-Spo3 was the major R-Spo family member produced in the intestine and it was predominantly produced by CD45-CD90+CD31+ lymphatic endothelial cells (LECs) in the lamina propria of the intestinal mucosa. Transcriptome analysis demonstrated that LECs highly expressed R-Spo receptor, Lgr5, suggesting an autocrine stimulatory loop in LECs. LECs were significantly reduced in number, and their R-Spo3 production was impaired in intestinal graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. The impaired production of R-Spo3 in the intestine may be a novel mechanism of delayed tissue repair and defective mucosal defense in intestinal GVHD. We demonstrate a novel role of intestinal LECs in producing R-Spondin3 to maintain intestinal homeostasis.
  • Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
    Clinical lymphoma, myeloma & leukemia, 18, 11, e469-e479, 2018年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-α (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. RESULTS: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. CONCLUSION: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors.
  • AMLにおけるWT1発現量と染色体・遺伝子異常の関連
    日高 大輔; 小野澤 真弘; 橋口 淳一; 宮下 直洋; 笠原 耕平; 藤澤 真一; 早瀬 英子; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 酒井 基; 石原 敏道; 今井 陽俊; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 小林 一; 岩崎 博; 清水 力; 近藤 健; 豊嶋 崇徳
    臨床血液, 59, 7, 964, 964, (一社)日本血液学会-東京事務局, 2018年07月
    日本語
  • Re-infection of Toxoplasma gondii after HSCT presenting lymphadenopathy resembling recurrence of lymphoma
    Junichi Hashiguchi; Masahiro Onozawa; Tomoaki Naka; Kanako C. Hatanaka; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Yoshihiro Matsuno; Takanori Teshima
    Transplant Infectious Disease, 20, 3, e12892, Blackwell Publishing Inc., 2018年06月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources.
    Ishio T; Sugita J; Tateno T; Hidaka D; Hayase E; Shiratori S; Okada K; Goto H; Onozawa M; Nakagawa M; Hashimoto D; Kahata K; Fujimoto K; Endo T; Kondo T; Teshima T
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 24, 10, 1990, 1996, Elsevier BV, 2018年06月, [査読有り]
    研究論文(学術雑誌)
  • Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
    Shuichiro Takahashi; Daigo Hashimoto; Eiko Hayase; Reiki Ogasawara; Hiroyuki Ohigashi; Takahide Ara; Emi Yokoyama; Ko Ebata; Satomi Matsuoka; Geoffrey R. Hill; Junichi Sugita; Masahiro Onozawa; Takanori Teshima
    Blood, 131, 18, 2074, 2085, American Society of Hematology, 2018年05月03日, [査読有り]
    英語, 研究論文(学術雑誌)
  • A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction.
    Miyashita N; Onozawa M; Hayasaka K; Yamada T; Migita O; Hata K; Okada K; Goto H; Nakagawa M; Hashimoto D; Kahata K; Kondo T; Kunishima S; Teshima T
    Annals of hematology, 97, 4, 629, 640, Springer Verlag, 2018年04月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Vitamin A–coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
    Tomohiro Yamakawa; Hiroyuki Ohigashi; Daigo Hashimoto; Eiko Hayase; Shuichiro Takahashi; Miyono Miyazaki; Kenjiro Minomi; Masahiro Onozawa; Yoshiro Niitsu; Takanori Teshima
    Blood, 131, 13, 1476, 1485, 2018年03月29日, [査読有り]
    英語, 研究論文(学術雑誌)
  • T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
    Shiratori S; Kosugi-Kanaya M; Hayase E; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Hashimoto D; Endo T; Kondo T; Teshima T
    Transplant immunology, 46, 21, 22, 2018年02月, [査読有り], [国際誌]
    英語
  • Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection
    Naoki Kawagishi; Goki Suda; Masahiro Onozawa; Megumi Kimura; Osamu Maehara; Jun Ito; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    JOURNAL OF HEPATOLOGY, 67, 5, 1106, 1108, 2017年11月, [査読有り]
    英語
  • 北海道大学における医学英語の取り組みと、学生の英語学習に対するモチベーションに関するアンケート調査
    小野澤 真弘; Houman Goudarzi; 武冨 貴久子; 稲葉 直子; 藤岡 容一朗; 川久保 和道; 折茂 達也; 金野 陽輔; 坊垣 暁之; 伊藤 智城; 本間 理央; 北市 雄士; 村上 壮一; 村上 学; 川畑 秀伸; 小華和 柾志; 大滝 純司
    医学教育, 48, Suppl., 139, 139, (一社)日本医学教育学会, 2017年08月
    日本語
  • Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
    Takahiro Tateno; Masahiro Onozawa; Junichi Hashiguchi; Takashi Ishio; Sayaka Yuzawa; Satomi Matsuoka; Mizuha Kosugi-Kanaya; Kohei Okada; Souichi Shiratori; Hideki Goto; Taichi Kimura; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Shinya Tanaka; Satoshi Hashino; Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE, 19, 4, 2017年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
    Naohiro Miyashita; Tomoyuki Endo; Masahiro Onozawa; Daigo Hashimoto; Takeshi Kondo; Katsuya Fujimoto; Kaoru Kahata; Junichi Sugita; Hideki Goto; Toshihiro Matsukawa; Satoshi Hashino; Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE, 19, 3, 2017年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance
    Liat Goldberg; Sheryl M. Gough; Fan Lee; Christine Dang; Robert L. Walker; Yuelin J. Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S. Meltzer; Peter D. Aplan
    GENES CHROMOSOMES & CANCER, 56, 6, 472, 483, 2017年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase
    M. Kanaya; Y. Hayashi; D. Hashimoto; T. Endo; J. Sugita; H. Ohigashi; J. Hashiguchi; T. Matsukawa; S. Matsuoka; M. Kosugi-Kanaya; H. Goto; M. Onozawa; K. Kahata; K. Fujimoto; T. Kondo; K. Akizawa; H. Shibuya; C. Shimizu; T. Teshima
    BONE MARROW TRANSPLANTATION, 52, 5, 778, 780, 2017年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Hepatol., 2017年04月, [査読有り]
  • Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities
    Makoto Ibata; Junko Iwasaki; Yoichiro Fujioka; Koji Nakagawa; Stephanie Darmanin; Masahiro Onozawa; Daigo Hashimoto; Yusuke Ohba; Shigetsugu Hatakeyama; Takanori Teshima; Takeshi Kondo
    CANCER SCIENCE, 108, 2, 200, 207, 2017年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Templated Sequence Insertion Polymorphisms in the Human Genome
    Masahiro Onozawa; Peter D. Aplan
    FRONTIERS IN CHEMISTRY, 4, 43, 43, 2016年11月, [査読有り]
    英語
  • Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD
    Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 104, 1, 117, 124, 2016年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy.
    Kasahara K; Onozawa M; Miyashita N; Yokohata E; Yoshida M; Kanaya M; Kosugi-Kanaya M; Takemura R; Takahashi S; Sugita J; Shigematsu A; Takahata M; Fujisawa S; Hashimoto D; Fujimoto K; Endo T; Kondo T; Teshima T
    Case Rep Hematol., 2016, 2373902, 5, Hindawi Limited, 2016年05月, [査読有り]
    英語, 研究論文(学術雑誌), We report a case of acute myeloid leukemia (AML) with two cytogenetically unrelated clones. The patient was a 45-year-old male who was diagnosed with acute monoblastic leukemia (AMoL). Initial G-band analysis showed 51,XY,+6,+8,inv(9)(p12q13)c,+11,+13,+19[12]/52,idem,+Y[8], but G-band analysis after induction therapy showed 45,XY,-7,inv(9)(p12q13)c[19]/46,XY,inv(9)(p12q13)c[1]. Retrospective FISH analysis revealed a cryptic monosomy 7 clone in the initial AML sample. The clone with multiple trisomies was eliminated after induction therapy and never recurred, but a clone with monosomy 7 was still detected in myelodysplastic marrow with a normal blast percentage. Both clones were successfully eliminated after related peripheral blood stem cell transplantation, but the patient died of relapsed AML with monosomy 7. We concluded that one clone was de novo AMoL with chromosome 6, 8, 11, 13, and 19 trisomy and that the other was acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) with chromosome 7 monosomy showing different responses to chemotherapy. Simultaneous onset of cytogenetically unrelated hematological malignancies that each have a different disease status is a rare phenomenon but is important to diagnose for a correct understanding of the disease status and for establishing an appropriate treatment strategy.
  • Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL
    Yongzhi Cui; Masahiro Onozawa; Haven R. Garber; Leigh Samsel; Ziyao Wang; J. Philip McCoy; Sandra Burkett; Xiaolin Wu; Peter D. Aplan; Crystal L. Mackall
    BLOOD, 125, 19, 2958, 2967, 2015年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Landscape of Insertion Polymorphisms in the Human Genome
    Masahiro Onozawa; Liat Goldberg; Peter D. Aplan
    GENOME BIOLOGY AND EVOLUTION, 7, 4, 960, 968, 2015年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection
    Takahata M; Hashino S; Onozawa M; Shigematsu A; Sugita J; Fujimoto K; Endo T; Kondo T; Tanaka J; Imamura M; Teshima T
    Transpl Infect Dis, 16, 5, 797, 801, 2014年10月, [査読有り]
  • DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier
    Margarida A. Santos; Robert B. Faryabi; Aysegul V. Ergen; Amanda M. Day; Amy Malhowski; Andres Canela; Masahiro Onozawa; Ji-Eun Lee; Elsa Callen; Paula Gutierrez-Martinez; Hua-Tang Chen; Nancy Wong; Nadia Finkel; Aniruddha Deshpande; Susan Sharrow; Derrick J. Rossi; Keisuke Ito; Kai Ge; Peter D. Aplan; Scott A. Armstrong; Andre Nussenzweig
    NATURE, 514, 7520, 107, +, 2014年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia
    Junko Iwasaki; Takeshi Kondo; Stephanie Darmanin; Makoto Ibata; Masahiro Onozawa; Daigo Hashimoto; Naoya Sakamoto; Takanori Teshima
    ANNALS OF HEMATOLOGY, 93, 9, 1473, 1481, 2014年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • NUP98-PHF23 Is a Chromatin-Modifying Oncoprotein That Causes a Wide Array of Leukemias Sensitive to Inhibition of PHD Histone Reader Function
    Sheryl M. Gough; Fan Lee; Fan Yang; Robert L. Walker; Yeulin J. Zhu; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Sven Bilke; Elise K. Wagner; John M. Denu; Yi Ning; Bowen Xu; Gang Greg Wang; Paul S. Meltzer; Peter D. Aplan
    CANCER DISCOVERY, 4, 5, 564, 577, 2014年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome
    Masahiro Onozawa; Zhenhua Zhang; Yoo Jung Kim; Liat Goldberg; Tamas Varga; P. Leif Bergsagel; W. Michael Kuehl; Peter D. Aplan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 111, 21, 7729, 7734, 2014年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia
    Sarah H. Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D. Aplan
    EXPERIMENTAL HEMATOLOGY, 41, 6, 518, 529, 2013年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Fungemia due to Trichosporon dermatis in a patient with refractory Burkitt's leukemia
    Satoshi Hashino; Shojiro Takahashi; Rena Morita; Hiroe Kanamori; Masahiro Onozawa; Takahito Kawamura; Kaoru Kahata; Takeshi Kondo; Issei Tokimatsu; Takashi Sugita; Koji Akizawa; Masahiro Asaka
    Blood Research, 48, 2, 154, 156, 2, 2013年, [査読有り]
    英語
  • Coexistence of pustular and vegetative pyoderma gangrenosum in a patient with myelodysplastic syndrome
    Wakana Omiya; Hideyuki Ujiie; Masashi Akiyama; Kentaro Izumi; Akio Shigematsu; Masahiro Onozawa; Hiroshi Shimizu
    EUROPEAN JOURNAL OF DERMATOLOGY, 22, 5, 711, 712, 2012年09月, [査読有り]
    英語
  • Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma
    Sarah H. Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L. Walker; Paul Meltzer; Peter D. Aplan
    BLOOD, 120, 5, 1048, 1059, 2012年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Illegitimate V(D)J recombination involving nonantigen receptor loci in lymphoid malignancy
    Masahiro Onozawa; Peter D. Aplan
    GENES CHROMOSOMES & CANCER, 51, 6, 525, 535, 2012年06月, [査読有り]
    英語
  • 骨髄異形成症候群を合併した壊疽性膿皮症の1例
    松村 若菜; 氏家 英之; 泉 健太郎; 秋山 真志; 清水 宏; 今野 哲; 重松 明男; 小野沢 真弘
    日本皮膚科学会雑誌, 122, 2, 377, 377, (公社)日本皮膚科学会, 2012年02月
    日本語
  • Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy
    S. Hashino; L. Morita; H. Kanamori; M. Takahata; M. Onozawa; M. Nakagawa; T. Kawamura; F. Fujisawa; K. Kahata; K. Izumiyama; M. Yonezumi; K. Chiba; T. Kondo; M. Asaka
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 31, 2, 173, 178, 2012年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Complete Remission Following Chemotherapy with Low-dose Cytosine Arabinoside and Macrophage Colony-stimulating Factor/Granulocyte Colony-stimulating Factor in a Patient with Relapsed Acute Myeloid Leukemia after Stem Cell Transplantation
    Kohei Okada; Asumi Higashiyama; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Sachiko Ando; Junji Tanaka; Satoshi Hashino; Masahiro Imamura
    INTERNAL MEDICINE, 51, 20, 2937, 2941, 2012年, [査読有り]
    英語, 研究論文(学術雑誌)
  • The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion
    Masahiro Onozawa; Kazumasa Ohmura; Makoto Ibata; Junko Iwasaki; Kohei Okada; Ikumi Kasahara; Keisuke Yamaguchi; Kanako Kubota; Shinichi Fujisawa; Akio Shigematsu; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Junji Tanaka; Yoshihiro Matsuno; Masahiro Asaka; Masahiro Imamura
    EUROPEAN JOURNAL OF HAEMATOLOGY, 86, 4, 347, 349, 2011年04月, [査読有り]
    英語
  • [Successful combination therapy by meropenem and colistin for multi-drug-resistant Pseudomonas aeruginosa infection after allogeneic bone marrow transplantation].
    Kanda M; Shigematsu A; Okada K; Kasahara I; Iwasaki J; Yamaguchi K; Onozawa M; Endo T; Akizawa K; Ishiguro N; Hashino S; Imamura M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 52, 3, 118, 123, 3, 2011年03月, [査読有り]
    日本語
  • [Successful treatment with reduced-intensity cord blood transplantation for acute myeloid leukemia with complete tetraploidy (92, XXXX)].
    Iwasaki J; Onozawa M; Takahashi S; Okada K; Takahata M; Shigematsu A; Kahata K; Kondo T; Hashino S; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 52, 3, 124, 128, 3, 2011年03月, [査読有り]
    日本語
  • Recurrence of Hydroxyurea-induced Leg Ulcer After Discontinuation of Treatment
    Kazuhiro Kikuchi; Ken Arita; Yasuki Tateishi; Masahiro Onozawa; Masashi Akiyama; Hiroshi Shimizu
    ACTA DERMATO-VENEREOLOGICA, 91, 3, 373, 374, 2011年, [査読有り]
    英語
  • Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.
    Shigematsu A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Yamaguchi K; Wakasa K; Takahata M; Goto H; Ito S; Takemura R; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Transplant infectious disease : an official journal of the Transplantation Society, 12, 5, 412, 420, 2010年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although bacterial infection is a major cause of death even after reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), little is known about the epidemiology and risk factors. The incidence of bacterial infection in 43 patients who received allogeneic bone marrow transplantation (BMT) using a RIC regimen was compared with that in 68 patients who received BMT using a myeloablative conditioning regimen, and risk factors for bacterial infection were identified. Before engraftment, incidences of febrile neutropenia (FN) and documented infections (DI) were significantly decreased in RIC patients (FN: 59.5% vs. 89.6%, P<0.01, DI: 4.8% vs. 17.9%, P<0.01). However, incidence of bacterial infection was significantly increased in RIC patients in the post-engraftment phase (53.8% vs. 11.1%, log-rank, P<0.01). Blood stream was the most frequent focus of infection in both groups. In multivariate analysis, RIC and acute graft-versus-host disease were revealed to be significant risk factors for bacterial infection in this phase. In summary, risk of bacterial infection after engraftment was significantly higher in RIC patients, although infection was decreased before engraftment, and we need to develop a RIC-specific strategy against bacterial infection after RIC SCT.
  • [Intravascular large B-cell lymphoma with massive pulmonary lesions].
    Higashiyama A; Hashino S; Onozawa M; Takahata M; Okada K; Kahata K; Taniguchi N; Nasuhara Y; Kubota K; Fujimoto N; Matsuno Y; Nishimura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 51, 5, 353, 356, 5, 2010年05月, [査読有り]
    日本語
  • Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): Clinical efficacy in high-risk patients
    Mutsumi Takahata; Satoshi Hashino; Kohei Okada; Masahiro Onozawa; Kaoru Kahata; Junichi Sugita; Akio Shigematsu; Takeshi Kondo; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Yoichi M. Ito; Junji Tanaka; Takao Koike; Masahiro Asaka; Masahiro Imamura
    AMERICAN JOURNAL OF HEMATOLOGY, 85, 4, 243, 248, 2010年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation
    Takeshi Kondo; Atsushi Yasumoto; Kotaro Arita; Jun-ichi Sugita; Akio Shigematsu; Kohei Okada; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Yukari Takeda; Masato Obara; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Norihiro Sato; Junji Tanaka; Satoshi Hashino; Takao Koike; Masahiro Asaka; Masahiro Imamura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 91, 2, 310, 321, 2010年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [Pyogenic spondylitis following unrelated hematopoietic stem cell transplantation].
    Mukaiyama Y; Hashino S; Onozawa M; Okada K; Takahata M; Kahata K; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 1706, 1710, 12, 2009年12月, [査読有り]
  • Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura.
    MORITA R; HASHINO S; OKADA K; TAKAHATA M; ONOZAWA M; KAHATA K; KONDO T; IMAMURA M; ASAKA M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 11, 1655, 1657, 11, 2009年11月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), A 53-year-old woman had demonstrated idiopathic thrombocytopenic purpura (ITP) and iron deficiency anemia (IDA) since 1978. Although she was treated with prednisolone for ITP and oral iron compounds for IDA, neither ITP nor IDA showed any improvement. Since her (13)C-urea breath test was positive, Helicobacter pylori (H. pylori) eradication therapy was performed in 2001. The therapy was effective for IDA but not for ITP. Analysis of cases such as this will be useful for clarifying the mechanisms underlying the development of ITP and IDA associated with H. pylori.
  • Regimen-Related Mucosal Injury of the Gut Increased the Incidence of CMV Disease after Allogeneic Bone Marrow Transplantation
    Akio Shigematsu; Atsushi Yasumoto; Satoshi Yamamoto; Junichi Sugita; Takeshi Kondo; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Shuichi Ota; Norihiro Sato; Mutsumi Takahata; Kohei Okada; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Takao Koike; Masahiro Asaka; Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15, 6, 679, 685, 2009年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Incidence and Risk of Postherpetic Neuralgia after Varicella Zoster Virus Infection in Hematopoietic Cell Transplantation Recipients: Hokkaido Hematology Study Group
    Masahiro Onozawa; Satoshi Hashino; Yoshifumi Haseyama; Yasuo Hirayama; Susumu Iizuka; Tadao Ishida; Makoto Kaneda; Hajime Kobayashi; Ryoji Kobayashi; Kyuhei Koda; Mitsutoshi Kurosawa; Nobuo Mosauji; Takuya Matsunaga; Akio Mori; Masaya Mukai; Mitsufumi Nishio; Satoshi Noto; Shuichi Ota; Hajime Sakai; Nobuhiro Suzuki; Tohru Takahashi; Junji Tanaka; Yoshihiro Torimoto; Makoto Yoshida; Takashi Fukuhara
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15, 6, 724, 729, 2009年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Endoscopic biliary drainage for choledocholithiasis in a patient with aplastic anemia before hematological engraftment after allogeneic transplantation.
    Okada K; Hashino S; Takahata M; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 5, 419, 423, 5, 2009年05月, [査読有り]
    日本語, 症例は30歳代,男性で,1997年発症の重症再生不良性貧血である。前医でmPSLパルス療法,ATG, cyclosporineで治療が行われたが,寛解・再燃を繰り返し,徐々に治療耐性となったため,同種骨髄移植目的に当院へ転院となった。移植前精査で,無症候性胆嚢胆石・総胆管結石を認めたが,白血球が低値であることから移植後に結石除去を行う方針とした。転院後,発熱を認め,G-CSFを連日投与しても好中球100/μl以下であり発熱性好中球減少症の状態であった。抗生剤投与により解熱後,骨髄非破壊的前処置でHLA一致ドナーより,非血縁者間同種骨髄移植を行った。移植後day 9に総胆管結石に伴う閉塞性胆管炎を発症した。無菌解除の上,内視鏡的にEBDチューブを挿入し,その後胆管炎症状は軽快した。day 24に骨髄生着し,血小板回復後のday 57にESTを施行し,総胆管結石の排石を行った。
    本症例は生着前の時期に閉塞性胆管炎を発症したが,内科的治療(EBD, 抗生剤投与)により救命しえた。移植前の無症候性胆道結石の扱いについて,定まった方針はなく,その適応に関しては,今後の症例の蓄積とさらなる検討が必要と考えられた。しかし一方で本症例により,たとえ移植前に手術や処置ができなくても,内科的治療により感染を乗り切ることができる可能性も示唆された。
  • Pseudomembranous tracheobronchial aspergillosis.
    Onozawa M; Takahashi S; Kanamori H; Kahata K; Kondo T; Hashino S; Asaka M
    Internal medicine journal, 39, 1, 65, 66, 2009年01月, [査読有り]
  • 薬剤性過敏症症候群類似の経過を辿った低ガンマグロブリン血症
    白井 慎一; 橋野 聡; 守田 玲菜; 小野澤 真弘; 川村 孝仁; 加畑 馨; 近藤 健; 今村 雅寛; 浅香 正博
    臨床血液, 50, 1, 23, 28, (一社)日本血液学会-東京事務局, 2009年01月
    日本語, 30歳男性。患者は上腹部痛および黒色便が出現し近医を受診、十二指腸潰瘍を認め入院後、肝機能障害と発熱、上半身に紅斑が出現し、肝生検で巨細胞性肝炎の所見からウイルス性肝炎を疑い、天然型インターフェロンα投与が行なわれた。その結果、皮疹は軽快したものの、リンパ球の減少をはじめガンマグロブリン低値、異型リンパ球出現、敗血症を認めたため、著者らの施設へ紹介入院となった。所見では発熱と多数の表在リンパ節腫脹がみられたが、3日目以降、解熱となり、リンパ節腫脹も縮小傾向となった。一方、FDG-PETを行なったところ、両側鼠径、脇窩リンパ節に集積が認められ、入院時の可溶性IL-2レセプター高値から悪性リンパ腫と考えたが、左鼠径リンパ節生検でDermatopathic lymphoadenopathyと診断された。病態が薬剤性過敏症症候群と類似していたためヒトヘルペスウイルス(HHV)-6型の抗体価測定を行なったところ、前医で160倍であったHHV-6 IgGは2560倍に上昇していた。以後、患者は症状が軽減し、退院となった。
  • [Hypogammaglobulinemia with a clinical course similar to that of drug-induced hypersensitivity syndrome].
    Shirai S; Hashino S; Morita R; Onozawa M; Kawamura T; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 1, 23, 28, 1, 2009年01月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 30-year-old man consulted a local hospital because of upper abdominal pain and tarry stool and was admitted because of duodenal ulcer and hepatic dysfunction. On the fifth hospital day, he developed fever and erythema on the upper body. Liver biopsy demonstrated giant cell hepatitis, and interferon alpha was therefore administered. Liver function improved, though total bilirubin increased to 22.3 mg/dl. The eruption and fever improved in the 3rd hospital week, deteriorated again in the 5th hospital week, and then improved again in the 8th hospital week. Thereafter, he was transferred to our hospital for detailed examination of atypical lymphocytosis, lymphopenia, and hypogammaglobulinemia. Many lymph nodes measuring about 1 cm were detected by palpation. After admission to our hospital, lymphoadenopathy and fever improved. We measured the level of HHV-6 antibody since the clinical course was similar to that of drug-induced hypersensitivity syndrome (DIHS). HHV-6 IgG was x2,560, although it had been x160 at the previous hospital. The clinical course appeared similar to that of DIHS, but drugs known to cause DIHS had not been administered.
  • HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection
    Masahiro Onozawa; Satoshi Hashino; Stephanie Darmanin; Kohei Okada; Rena Morita; Mutsumi Takahata; Akio Shigematsu; Kaoru Kahata; Takeshi Kondo; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 11, 1226, 1230, 2008年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma
    Rena Morita; Satoshi Hashino; Shinichi Shirai; Noriaki Fujita; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 88, 2, 248, 250, 2008年09月, [査読有り]
    英語
  • A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
    Shiratori S; Yasumoto A; Tanaka J; Shigematsu A; Yamamoto S; Nishio M; Hashino S; Morita R; Takahata M; Onozawa M; Kahata K; Kondo T; Ota S; Wakasa K; Sugita J; Koike T; Asaka M; Kasai M; Imamura M
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14, 7, 817, 823, 7, 2008年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis. Recently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the outcome. We retrospectively analyzed 15 patients with ATL who had received allo-HSCT in 2 institutions in Hokkaido, Japan. The median age of the patients was 57 years. The estimated 3-year overall survival (OS) and progression-free survival (PFS) rates were 73.3% and 66.7%, respectively. Calcineurin inhibitor dosage was reduced and administration was discontinued abruptly in 6 of the 15 patients for disease control; as a result, 4 (66.7%) of the 6 patients achieved complete response (CR) or partial response. Therefore, a graft-versus-leukemia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression. Thirteen of the 15 patients were followed up by monitoring HTLV-1 proviral DNA levels. In 10 of the 11 patients with positive HTLV-1 proviral DNA before allo-HSCT, HTLV-1 proviral DNA became undetectable at least once after allo-HSCT, and only 1 of the 5 patients in whom HTLV-1 proviral DNA became detectable after allo-HSCT relapsed. Compared to the results of past studies, these results show that allo-HSCT greatly improved the prognosis of ATL and suggest a contribution of the induction of a GVL effect.
  • Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia
    Akio Shigematsu; Takeshi Kondo; Satoshi Yamamoto; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Soichi Shiratori; Shuichi Ota; Masato Ohara; Kentaro Wakasa; Mutsumi Takahata; Yukari Takeda; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Takao Koike; Masahiro Asaka; Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 5, 568, 575, 2008年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer
    Satoshi Hashino; Sumiko Kobayashi; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Koh Izumiyama; Kaoru Kahata; Takeshi Kondo; Masahiro Asaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 13, 2, 176, 180, 2008年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [Granulocyte transfusion for the treatment of prolonged pneumonia in a patient with MDS-RAEB-2 at allogeneic hematopoietic stem cell transplantation].
    Morita R; Hashino S; Takahashi S; Kanamori H; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 49, 2, 89, 93, 2, 2008年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We report that granulocyte transfusion (GTX) was effective for prolonged pneumonia at allogeneic bone marrow transplantation. A 58-year-old man with MDS-RAEB-2 was admitted to our hospital for allogeneic bone marrow transplantation. He was complicated with pneumonia, which was not improved with G-CSF and antibiotics. We therefore decided to perform a GTX transplantation. During the period of neutropenia, pneumonia did not deteriorate. A combination of allogeneic stem cell transplantation and GTX is expected not only to improve transplantation results but also to expand the adaptation for transplantation. However, detailed investigation of the effect of GTX in allogeneic stem cell transplantation should be performed, and more cases should be accumulated.
  • Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation
    Satoshi Hashino; Lena Morita; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 87, 1, 91, 97, 2008年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients
    Masahiro Onozawa; Satoshi Hashino; Mutsumi Takahata; Fumie Fujisawa; Takahito Kawamura; Masao Nakagawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
    JOURNAL OF CLINICAL MICROBIOLOGY, 44, 12, 4441, 4443, 2006年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Successful treatment with allogeneic peripheral blood stem cell transplantation and granulocyte transfusion for severe aplastic anemia with sinusitis
    M Takahata; T Fukuhara; A Shingematsu; M Onozawa; Y Yamamoto; T Miyake; Maekawa, I
    TRANSPLANT INFECTIOUS DISEASE, 8, 1, 44, 48, 2006年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients
    Shuichi Ota; Manabu Musashi; Keiichi Kondo; Nobuyasu Toyoshima; Tomomi Toubai; Masahiro Onozawa; Akio Mori; Satoshi Hashino; Junji Tanaka; Kazuhiko Matsuno; Masahiro Imamura; Masahiro Asaka
    ACTA HAEMATOLOGICA, 116, 1, 8, 18, 2006年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: A case in neurofibromatosis type 1
    M Onozawa; T Fukuhara; M Minoguchi; M Takahata; Y Yamamoto; T Miyake; K Kanagawa; M Kanda; Maekawa, I
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 35, 9, 559, 563, 2005年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Case 2. Thalidomide-induced interstitial pneumonitis
    M Onozawa; S Hashino; S Sogabe; M Haneda; H Horimoto; K Izumiyama; T Kondo; LP Aldana; K Hamada; M Asaka
    JOURNAL OF CLINICAL ONCOLOGY, 23, 10, 2425, 2426, 2005年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection
    M Onozawa; S Hashino; K Izumiyama; K Kahata; M Chuma; A Mori; T Kondo; N Toyoshima; S Ota; S Kobayashi; S Hige; T Toubai; J Tanaka; M Imamura; M Asaka
    TRANSPLANTATION, 79, 5, 616, 619, 2005年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Usefulness of magnifying endoscopic evaluation of the terminal ileum for a patient with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    M Onozawa; M Yonezumi; M Kawarazaki; K Izumiyama; K Chiba; T Kondo; S Ota; S Kobayashi; M Kato; S Hashino; J Tanaka; M Imamura; M Asaka
    ANNALS OF HEMATOLOGY, 84, 2, 106, 109, 2005年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Aleukemic leukemia cutis in a patient with Philadelphia chromosome-positive biphenotypic leukemia
    M Onozawa; S Hashino; H Kanamori; K Izumiyama; M Yonezumi; K Chiba; T Kondo; T Fukuhara; J Tanaka; M Imamura; M Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 80, 3, 278, 280, 2004年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 45, 10, 1105, 1110, 10, 2004年10月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), Imatinib mesylate (imatinib) has shown significant effects in patients with chronic myelogenous leukemia. However, hematological toxicity often occurs and requires dosage reduction or discontinuation of imatinib treatment. A patient with chronic myelogenous leukemia in the blastic crisis received granulocyte-colony stimulating factor (G-CSF) simultaneously with imatinib. The patient was continuously treated with imatinib and G-CSF and achieved remission without any severe infection or neutropenia. There are a few reports on the efficacy of combined therapy with G-CSF and imatinib; however, the results in our case are rare suggesting that the use of G-CSF is effective for preventing severe infection. G-CSF enables continuous treatment with high-dose imatinib.
  • Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex
    T Kondo; M Kobayashi; J Tanaka; A Yokoyama; S Suzuki; N Kato; M Onozawa; K Chiba; S Hashino; M Imamura; Y Minami; N Minamino; M Asaka
    JOURNAL OF BIOLOGICAL CHEMISTRY, 279, 26, 27315, 27319, 2004年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [Relapse of biphenotypic leukemia confirmed by molecular study].
    Onozawa M; Hashino S; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Tanaka J; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 45, 2, 161, 163, 2, 2004年02月, [査読有り]
    日本語, A 60-year-old woman was admitted to our hospital to receive treatment for relapse of biphenotypic leukemia 4 years after initial presentation. Bone marrow examination revealed 53.5% lymphoblasts, which were classified as ALL-L2 with normal karyotype. Surface markers of lymphoblasts were positive for both B-cell and myeloid lineage. Immunoglobulin heavy chain and T-cell receptor gene rearrangements were investigated by PCR. Clonal rearrangement of TCRδ Vδ2-Dδ3 was detected. The same clonal rearrangement of TCRδ was found using frozen initial leukemic cells. Her leukemia was confirmed as not secondary leukemia but relapse of the initial clone. Detection of the rearrangement was also useful as a patient-specific marker for minimal residual disease.
  • Insertion (21;8)(q22;q22q22): a masked t(8;21) in a patient with acute myelocytic leukemia
    M Onozawa; T Fukuhara; M Nigo; A Takeda; M Takahata; Y Yamamoto; T Miyake; M Kanda; Maekawa, I
    CANCER GENETICS AND CYTOGENETICS, 147, 2, 134, 139, 2003年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL
    M Onozawa; T Fukuhara; M Takahata; Y Yamamoto; T Miyake; Maekawa, I
    ANNALS OF HEMATOLOGY, 82, 9, 593, 595, 2003年09月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
■ 主な担当授業
  • 社会医学研究Ⅱ, 2024年, 博士後期課程, 医学研究科
  • 臨床医学概論, 2024年, 修士課程, 医学院
  • 社会医学研究Ⅰ, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 医学英語演習, 2024年, 学士課程, 医学部
  • 統合・血液学, 2024年, 学士課程, 医学部
■ 所属学協会
  • 日本人類遺伝学会
  • 日本輸血学会
  • 日本造血細胞移植学会
  • 日本臨床血液学会
  • 日本血液学会
  • 日本内科学会
  • 日本医学教育学会
  • 日本臨床腫瘍学会
  • 日本臨床検査医学会
  • 欧州血液学会
  • 米国血液学会
■ 共同研究・競争的資金等の研究課題
  • NUP98::NSD1白血病の治療抵抗性の解明と新規治療法の開発
    科学研究費助成事業
    2023年04月01日 - 2026年03月31日
    松川 敏大; 平林 真介; 小野澤 真弘
    北海道白血病ネットのヒト臨床検体からNUP98::NSD1をクローニングした。NUP98::NSD1全長が非常に長いため、全長をそのままクローニングを行うことは困難であった。まず、全長を前半部分と後半部分に分けてクローニングを行い、前半・後半部分をそれぞれPCRで増幅しベクターを制限酵素で切断した。切断部分にNUP98::NSD1の前半・後半部分を挿入し、形質転換後にプラスミド抽出を行った。それぞれの配列をサンガーシークエンスで確認すると一部に塩基置換が認められ、PCR法などによる修復を行ない、シークエンスを復元することができた。前半部分と後半部分を結合させ、全長をサンガーシークエンスで確認し、変異のないことを確認した。
    当初、出来上がったNUP98::NSD1をB細胞系細胞株であるBa/F3に遺伝子導入したのちに薬剤選択により細胞株を樹立した。しかし、樹立したと思われる細胞株においてNUP98::NSD1の融合蛋白を確認できなかった。同様の手法で、他のヒト細胞株にも遺伝子導入を行ったが、同様に融合蛋白を認めることが困難であった。
    薬剤耐性株は樹立できているが目的とする蛋白の発現が見られない。
    この原因については判然とはしていないが、目的とする蛋白の発現が見られない以上は薬剤耐性にはなっているが何らかの原因で融合蛋白が作成できていないと考えた。
    現在は、別のベクターに乗せ替えを行ってから、再度遺伝子導入を行い、今後NUP98::NSD1陽性ヒト細胞株の樹立を目指すことを目標としている。
    日本学術振興会, 基盤研究(C), 北海道大学, 23K07802
  • 慢性骨髄性白血病におけるDMR達成率向上の治療戦略の開発
    科学研究費助成事業 基盤研究(C)
    2021年04月01日 - 2025年03月31日
    近藤 健; 小野澤 真弘
    慢性骨髄性白血病はチロシンキナーゼ阻害剤の有用性が確立した疾患である。チロシンキナーゼ阻害剤での治療により長期的な効果が期待出来、一部の症例では薬剤を中止しても再発が認められないtreatment free remissionが達成できることが確立している。一方、十分な治療効果が得られない症例も存在し、これらの症例対する治療法の開発が求められている。これまでにエピゲノム関連遺伝子の変異がTKIの治療成績に関連することが報告されており、本研究では臨床的に検出されるASXL1, DNMT3Aの変異に焦点を当てて解析を進めている。
    1)ASXL1, DNMT3A遺伝子をテトラサイクリン発現誘導システムのレトロウイルスベクターpRetroX-TetOneに組み込み、野生型、変異型のテトラサイクリン発現誘導ベクターを作成し、TKI感受性CML由来細胞株(K562細胞、KU812細胞)に導入し、テトラサイクリンで発現誘導可能な目的遺伝子を発現する安定形質転換細胞株を樹立した。
    2)これらの細胞株を用いて、ドキシサイクリン有無でのTKI感受性の解析を行ったところ変異型ASXL1または変異型DNMT3Aの誘導においてTKI感受性の低下が確認された。
    3)これらの細胞を用いて、導入遺伝子の発現誘導の有無により発現変動が生じる遺伝子群をマイクロアレイを用いて
    薬剤感受性細胞と薬剤抵抗性細胞の遺伝子プロファイルを解析し、細胞表面分子や細胞内シグナル分子などの発現変動を確認している。
    現在、TKI抵抗性に関連すると推定される遺伝子の解析を進めている。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K08362
  • 小児・AYA世代におけるMDSの発生機序と治療戦略の解明
    科学研究費助成事業 基盤研究(C)
    2021年04月01日 - 2024年03月31日
    平林 真介; 真部 淳; 鳴海 覚志; 三谷 絹子; 小野澤 真弘
    本研究は本邦の小児からAYA世代のMDSの先天性素因の同定と臨床データを合わせて統合解析を行い、発生機序の解明と治療戦略へ繋げる。成人MDSは加齢性変化の影響が大きいが、小児・AYAのMDSは遺伝的要因による造血幹細胞の脆弱性から、感染、炎症による造血ストレス環境、内因性アルデヒド代謝の違いなどにより、骨髄不全の進行と早期のクローン性造血に至ると考えられる。遺伝、環境とも多様な因子があり、未解明な部分が多い。小児科・血液内科・基礎研究を一元的に行い、先天性素因を把握する。令和3年度は症例集積と解析を進めていった。その中で、染色体異常der(1;7)(q10;p10)が、小児、AYA世代の主要な先天性素因であるGATA2異常症においてmonosomy 7に次ぐ特徴であることがわかった。これはドイツ、米国との国際共同研究に加わり、多数例の検討を行った結果であり、そのまま論文発表に至ることができた(Blood.2021;138(23):2441-2445.)。今後とも検討すべき課題はあり、国際共同研究を発展させるべく協力を継続していく。今年度も小児領域、成人領域をまたがる形で、小児科、血液内科との共同研究を開始し、遺伝子解析系とデータベースの構築に努める。また引き続き先天性素因を疑わせる核型異常に注目して、小児、AYA世代のMDS、AML症例を中心に造血転写因子の生殖細胞系列バリアントの解析を開始する。先行解析として20例の当該症例において解析系の構築を進めている。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K08361
  • 難治性白血病発症機序の解明
    科学研究費助成事業 基盤研究(C)
    2020年04月01日 - 2023年03月31日
    小野澤 真弘
    FLT3遺伝子内縦列重複(ITD)変異陽性は急性骨髄性白血病(AML)の強力な予後不良因子であり、同種造血細胞移植によっても充分な予後の改善が得られていない。FLT3阻害剤も上市されているが、その効果は短期的、限定的であり、さらなる病態の理解と新たな治療戦略の開発が必要である。本研究ではFLT3-ITDを生じる分子メカニズムに焦点を当てて研究を進めている。本研究課題ではアンプリコンシークエンスにより、高感度でFLT3-ITDを検出する方法を開発した。ITD変異の集積部位であるFLT3 exon14, 15領域をPCR増幅し、増幅産物を次世代シークエンスで深くシークエンスを行うことで0.01%のFLT3-ITDアリルを検出可能である。PCRエラーによる偽陽性の可能性が排除できない1塩基置換とは異なり、特徴的なFLT3-ITD変異は偽陽性がなく、低頻度でも腫瘍変異と同定可能である。急性骨髄性白血病検体で検討したところ、通常のキャピラリーシークエンスでは検出できない1%未満のアリル頻度のFLT3-ITD変異が、FLT3変異陰性と判定されていた症例にも存在することを見出した。ITD長の異なる複数の低頻度FLT3-ITDがオリゴクローナルに存在する症例があることも明らかとなった。また、細胞株を用いた検討では、CRISPR-Cas9システムを用い、人工的にFLT3-ITD変異を作成することに成功した。
    日本学術振興会, 基盤研究(C), 北海道大学, 20K08745
  • 次世代シークエンスによる再発難治性急性白血病のゲノム構造の解析
    科学研究費助成事業 基盤研究(C)
    2016年04月01日 - 2019年03月31日
    小野澤 真弘
    本研究では白血病細胞の放射線、化学療法によるDNA損傷に起因するゲノム構造の変化について、次世代シークエンス技術を用いて網羅的に解析することを目標とした。体細胞性変異としてのゲノム損傷修復の蓄積は、癌抑制遺伝子の発現喪失などを通して発癌や治療抵抗性の獲得に直接関わっている可能性がある。細胞株を用いたCRISPRによる部位特異的なDNA切断では、DNA二重鎖切断部位が様々な長さの欠失あるいは配列挿入で修復されることを確認した。2種類のヒト白血病細胞株とその派生細胞株で全ゲノムシークエンスを行なった。腫瘍特異的な挿入欠失を含むリードを抽出する方法を検討し解析を進めている。
    日本学術振興会, 基盤研究(C), 北海道大学, 16K09836
  • テロメラーゼによるDNA二重鎖切断修復機構の解明
    科学研究費助成事業 研究活動スタート支援
    2014年08月29日 - 2016年03月31日
    小野澤 真弘; アプラン ピーター; 宮下 直洋
    テロメラーゼは染色体末端でのテロメア配列伸長以外に様々な生理的機能を持つ。テロメラーゼがDNA修復に関わる事が推察されてきたが、これまで直接的な証明はなかった。本研究では細胞株を用い、実験的に導入したDNA二重鎖切断が、テロメア配列(TTAGGG)nの挿入で修復される事を見いだした。また、テロメア配列挿入がヒト遺伝多型の一つであることを見いだした。染色体非末端部にあるテロメア配列はDNA損傷修復の痕跡と考えられ、進化的に保存された遺伝子修復機序と考えられる。
    日本学術振興会, 研究活動スタート支援, 北海道大学, 26890001
  • B型肝炎既往者における造血細胞移植後のHBV再燃予防のための臨床介入試験
    科学研究費助成事業 若手研究(B)
    2008年 - 2009年
    小野澤 真弘
    HBV感染症において、HBe抗体の出現とHBe抗原の消失は、セロコンバージョンと言われ、肝炎症状の軽快時期と一致するため臨床上重要なポイントである。それに引き続き、HBs抗体が出現しHBs抗原が消失すると、HBV感染症は治癒したものと考えられていた。近年このような既往感染者でも肝組織内にはPCRで検出可能なHBVが残存することが明らかとなった。免疫抑制状態でこのようなHBVが再燃し、再びHBs抗原陽性、HBs抗体消失することをHBVリバースセロコンバージョン(HBV-RS)という。HBV感染既往者で、同種造血細胞移植後に続いて起きるHBV-RSは、移植後期に高頻度に起きる合併症である。我々は38例のHBV感染既往の同種造血細胞移植患者について、後方視的症例対照試験を行った。ワクチン療法を開始する2003年以前の13症例を歴史的コントロール群とし、2003年以降13例においてHBワクチンの接種を行った(ワクチン群)。2003年以降でワクチン接種を行わなかった12例を非ワクチン群とした。歴史的コントロール群の13例中8例、非ワクチン群の12例中3例でHBV-RSを起こしたが、ワクチン群からは1例もHBV-RS発症を認めなかった。移植後3年でのHBV-RS発症率は歴史的コントロール、非ワクチン群、ワクチン群で各々41%, 39%, 0%だった。同種造血細胞移植後のHBワクチンはHBV-RS予防に効果があると考えられた。
    日本学術振興会, 若手研究(B), 北海道大学, 研究代表者, 競争的資金, 20790667
  • 造血細胞移植後感染症
    その他の研究制度
    競争的資金
  • Hematological cell transplantation
    The Other Research Programs
    Hematological cell transplantation
    競争的資金